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Extracellular vesicles are a heterogeneous family of vesicles, generated from different 
subcellular compartments and released into the extracellular space. Composed of a lipid 
bilayer encompassing both soluble cytosolic material and nuclear components, these 
organelles have been recently described as novel regulators of intercellular communication 
between adjacent and remote cells. Due to their diversified composition and biological 
content, they portray specific signatures of cellular activation and pathological processes, 
their potential as diagnostic and prognostic biomarkers has raised significant interest in 
cardiovascular diseases. Circulating vesicles, especially those released from platelets, 
leukocytes, and endothelial cells are found to play a critical role in activating several 
fundamental cells within the vasculature, including endothelial cells and vascular smooth 
muscle cells. Their intrinsic activity and immunomodulatory properties lends them to 
not only promote vascular inflammation, but also enhance tissue regeneration, vascular 
repair, and indeed resolution. In this review we aim to recapitulate the recent findings 
concerning the roles played by EVs that originate from different circulating cells, with 
particular reference to their action on the endothelium. We focus herein, on the interaction 
of platelet and leukocyte EVs with the endothelium. In addition, their potential biological 
function in promoting tissue resolution and vascular repair will also be discussed.
Keywords: extracellular vesicles, vascular inflammation, endothelial cell, tissue resolution, tissue repair
HETEROGENEITY OF EXTRACELLULAR VESICLES 
Virtually all cell types have the ability to release small membrane-derived packages of information 
from their surface (Van der Pol et al., 2012). These nano-packages, termed extracellular vesicles (EVs), 
represent a key mechanism of paracellular communication (Deatherage and Cookson, 2012) and are 
attributed numerous roles in regulating both physiological and pathological functions (Van der pol 
et al., 2012; Yáñez-Mó et al., 2015; Hyenne et al., 2019). First investigated by Peter Wolf in 1967, 
EVs were described for their prothrombotic functions and coined “platelet dust” (Hargett and Bauer 
2013). We now know their functions to be remarkably diverse, largely owing to their generation 
from distinct processes (Beaudoin and Grondin 1991) resulting in three sub-groups that have 
overlapping characteristics (Van der Pol et al., 2016). Exosomes being the smallest members of the 
group, range in size from 40 to 100 nm in diameter. They encompass specific cytosolic products that 
are packaged into vesicles through the inward budding of multi-vesicular bodies (MVBs) and instead 
of being degraded, are routed to and released from the plasma membrane (van der Pol et al., 2012). 
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Microvesicles (MV), also termed “microparticles” are larger in 
size, ranging from 150 to 1,000 nm and are generated through 
direct budding at the plasma membrane (Van der Pol et al., 2012). 
The final group member; apoptotic bodies, arise as a consequence 
of extensive membrane budding that occurs during apoptosis; a 
homeostatic mechanism typically executed in response to overt-
stress or as part of the normal cell life-cycle, with resultant vesicle 
size ranging from 1 to 5 µm (Elmore, 2007) (Figure 1).
EV heterogeneity is derived from their apparent size, 
membrane composition, and contents; a complex mix of 
bioactive lipids, RNAs, and proteins (Mack et al., 2000; Ng et al., 
2013; Dalli et al., 2013). This diversity is largely dependent on 
cell activation state and it's environment (Peterson et al., 2008; 
Dalli et al., 2013). EVs bear markers pertaining to their cell of 
origin; which can be used to help identify them. EVs not only 
facilitate the intercellular transfer of cargo, but also membrane-
bound receptors and antigen presentation complexes (Li et  al., 
2013b; Rauschenberger et al., 2016). Intriguingly, EVs can 
exhibit miRNA, lipid and protein profiles distinct from their 
cell of origin, suggesting they are not just passive vehicles of the 
cell’s current proteome, transcriptome, and lipidome, but are 
actively and specifically packaged with purposeful mediators. 
Gidlöf et al., revealed active packaging of miR-22 into EVs and 
its active depletion from platelets with increased activation 
(Collino et al., 2010; Diehl et al., 2012; Gidlöf et al., 2013). 
More recent studies have reported single stranded and double 
stranded DNA in EV fractions (Guescini et al., 2010; Balaj 
et  al., 2011; Thakur et al., 2014). EV-associated DNAs have so 
far been attributed with the progression of pathology, although 
this certainly needs more investigation. Additionally, Fonseca et 
al., described and characterised a variety of metabolic proteins 
in EV fractions that are able to control the metabolic functions 
of target cells and tissues (Fonseca et al., 2016), adding another 
level of complexity to the EV-intercellular signaling paradigm. 
EVs could therefore be more pertinently considered as discrete 
extracellular organelles—comprised of a collection of factors that 
initiate specialised signals in recipient cells (Ludwig and Giebel 
2012; Yáñez-Mó et al., 2015).
Differentiating members of the EV family based on specific 
characteristics has long been a point of contention in the field. 
Recently, a systematic and comprehensive proteomic analysis of 
EVs was performed, using rigorous isolation procedures including 
flotation in sucrose, iodixanol gradients or immunosorting 
which has provided a detailed classification system for the 
different EV subsets (Kowal et al., 2016). This analysis selected 
large EVs pelleting at low centrifugal speed (2,000×g), medium 
at intermediate speed (10,000×g), and small at high speed 
(100,000×g). Among the small EVs, four subcategories were 
described: EVs coenriched in CD63, CD9, and CD81 alongside 
endosomal markers; those devoid of CD63 and CD81 but 
FIGURE 1 | Extracellular vesicle biogenesis. Microvesicles: Activation of receptors coupled to Ca2+ signaling promotes phoshatidylserine (PtdSer) exposure 
on the outer leaflet by modulating flippase, floppase, and scramblase activity. Ca2+-activated μ-calpain cleaves cortical actin and activation of Rho-associated 
protein kinases (ROCK) by RhoA and NFkB induces cytoskeletal contraction. Released vesicles contain membranous proteins, and cytosolic components while 
budding from the membrane. Exosomes: two separate mechanisms are described. (A) ESCRT dependent and (B) ESCRT independent biogenesis. GTP, guanine 
triphosphate; IL-1β, interleukin-1β; PAMP, pathogen-associated molecular pattern; ROCK, Rho-associated protein kinases; TNFα, tumor necrosis factor α; 
AP, apoptotic body; MVB, multi-vesicular body; TLR, toll like receptor; PtdSer, phosphatidylserine; SMPD-3, sphingomyelin phosphodiesterase 3.
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enriched in CD9 (associated with plasma membrane and/or early 
exosomal markers); those devoid of CD63, CD81, and CD9 and 
finally those enriched in extracellular proteins or serum proteins. 
Interestingly, the data would suggest the latter two subtypes do 
not correlate with markers for exosome biogenesis. Syntenin-1 
and TSG101 were associated with tetraspanin-enriched 
exosomes. In light of these findings, EVs released from different 
cell types and indeed from the same cells, may be enriched both 
qualitatively and quantitatively in different tetraspanin content 
(Kowal et  al., 2016). This improved methodology provides a 
more precise determination of the molecular composition of EVs 
and suggests that the classical tetraspanin-enriched exosomes 
may contain a less diverse EV repertoire that previously assumed 
(Jeppesen et al., 2019).
THE BIOGENESIS OF EXTRACELLULAR 
VESICLES
Exosomes
Exosomes and microvesicles have very distinct methods 
of biogenesis, although the following description is still up 
for debate. Two mechanisms of exosome generation have 
been identified, the endosomal sorting complexes required 
for transport (ESCRT) dependent and ESCRT independent 
biogenesis as depicted in Figure 1. The ESCRT machinery was 
first described in dendritic cells (Tamai et al., 2010) for its role 
in the formation of exosomes and intra-luminal vesicles (ILV). 
Firstly, ubiquitinated transmembrane cargos are clustered into 
microdomains of the limiting membrane of MVB by ESCRT-
0, ESCRT-I subunits, via ESCRT-II, which recruits ESCRT-
III sub-complexes to finally enable budding and fusion of this 
microdomain. The classical ESCRT pathway can interact with 
syntenin and the ESCRT accessory protein ALIX, which links 
cargo and the ESCRT-III subunit vacuolar protein sorting-
associated protein 32 (VPS32) (Maki et al., 2016). Although the 
ESCRT-machinery is a well described mechanism for exosome 
formation, studies show depletion of its components are not 
sufficient to prevent the production, nor the release of exosomes 
(Stuffers et al., 2009).
The ceramide-mediated generation of EVs was the first 
ESCRT-independent mechanism of exosome biogenesis 
described. Ceramide is negatively charged and impresses a 
natural negative curvature on the membrane, thus generating 
membrane subdomains (Goñi and Alonso 2009). Furthermore, 
ceramide can be metabolised to sphingosine-1-phosphate, 
activating the G-protein coupled sphingosine-1-phosphate 
receptor which has been identified as a key player in ILV cargo 
loading (Kajimoto et al., 2013). Another family of proteins 
involved in ESCRT-independent exosome biogenesis are the 
tetraspanins, with particular attention to CD63 which is mainly 
enriched on the exosome membrane. This process has so far 
been reported for melanocytes, melanoma cells, and fibroblasts 
from patients with Down syndrome (Van Niel et al., 2018). 
Other tetraspanins described to play a role in the formation of 
microdomains and exosome cargo sorting are: CD81, CD82, 
and CD9 (Chairoungdua et al., 2010). These proteins can 
cluster and form dynamic rafts with other cytosolic proteins or 
other tetraspanins, thus leading to cytoskeletal remodeling and 
enabling microdomain formation (Buschow et al., 2009; Charrin 
et al., 2014). However, recent studies underlined how tetraspanins 
also control the intracellular routing of cargoes, such as integrins 
in MVBs, which suggests their absence on membranes may 
also influence exosome generation. Both ESCRT-dependent 
and independent mechanisms might function in exosome 
biogenesis and their specific contributions may be different or 
alter depending on the cell and the cargo (Odintsova et al., 2013).
The involvement of these distinct machineries is also related 
to the balance between lysosomal degradation and exosome 
secretion. Indeed, the different components of the ESCRT 
machinery are related with lysosomal fusion and degradation 
of MVBs, whilst the syndecan-syntenin-ALIX pathway seems 
to be restricted to exosome fusion with the plasma membrane 
and subsequent secretion (Baietti et al., 2012). Recently, 
calcium dependent SNARE and synaptotagmin family member 
proteins, have been related with MVB fusion to the plasma 
membrane in order to release ILVs as exosomes (Hay and 
Scheller 1997). Of course, there is an indispensable requirement 
for the cytoskeletal network and the involvement of molecular 
motors or switches such as myosins, dynein, kinesins, and small 
GTPases in intracellular transport (Bonifacino and Glick 2004; 
Hessvik et al., 2016).
Plasma Membrane-Derived Extracellular 
Vesicle Biogenesis
Several pathways are proposed to be involved in the generation 
of vesicles from the surface of the plasma membrane. Ligand-
induced Ca2+ influx was one of the first mechanisms described 
in the exocytosis process. Exogenous stimuli, such as: adenosine 
triphosphate (ATP), thrombin, and lipopolysaccharide (LPS), all 
strongly induce intracellular Ca2+, triggering potent EV release. 
This can be significantly reduced with the bivalent cation chelator, 
BAPTA-AM suggesting any ligand which induces biologically 
significant Ca2+ release into the cytosol could also induce 
exocytosis. Furthermore, cell surface vesicle release can also be 
initiated with Ca2+ ionophores such as A23187 (Heemskerk et al., 
1997; Pasquet et al.,1998).
Plasma membrane rearrangements, including changes in 
lipid and protein content are also required for the biogenesis of 
membrane-derived vesicles. Different Ca2+ dependent enzymatic 
machineries such as aminophospholipid translocases (flippase 
and floppases), scramblases, and calpain are responsible for 
modifying the membrane phospholipid symmetry and causing 
physical twisting of the membrane (mostly translocation 
of phosphatidylserine [PtdSer] from the inner to the outer 
membrane leaflet), resulting in membrane budding and EV 
formation (Johnstone et al., 1989) as shown in Figure 1. A 
key scramblase reported for EV budding and PtdSer exposure 
is TMEM16F, a Ca2+-activated chloride channel (Whitlock 
and Hartzell, 2017). Genetic defects in the activity of this lipid 
scramblase, suppress the exposure of PtdSer on platelets and 
thus the production of procoagulant-containing membrane 
bound vesicles (Suzuki et  al., 2010). Despite this, studies have 
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shown vesicle release can still occur even when membrane lipid 
asymmetry is maintained (Jimenez et al., 2003; Connor et al., 
2010). These findings indicate a role for other mechanisms in the 
formation of membrane-derived EVs. Cholesterol, for example, 
an important lipid component that regulates membrane fluidity, 
was observed to be abundant in membrane bound vesicles and 
depletion impaired vesicle formation in activated neutrophils 
(Pfrieger and Vitale, 2018).
Of course, in addition to lipids, cytoskeletal components 
and their regulators are required for membrane bound vesicle 
biogenesis. The activity of the Rho GTPases and of the Rho-
associated protein kinase (ROCK) are required for membrane-
derived vesicle biogenesis, due to their important roles as 
regulators of actin dynamics (Li et al., 2012a); RhoA activation 
seems to be specifically required during membrane-bound vesicle 
formation (Ishizaki et al., 1996). RhoA binding to GTP initiates 
a conformational change in ROCK (Matsui et al., 1996), leading 
to increased ROCK kinase activity that in turn phosphorylates 
myosin light chain phosphatase and myosin light chain (Leung 
et al., 1996). Increased association of myosin light chain to actin 
filaments results in cytoskeletal contractility and membrane 
budding (Coleman et al., 2001).
The resultant EVs generated are protected by a phospholipid 
bilayer, which equips them with a unique protection against 
rapid degradation, as such they can be utilised at sites close to 
release or can travel great lengths reaching distant targets. Upon 
reaching their target, EVs can be taken up by membrane fusion 
or endocytosis. Hyenne et al. demonstrated using a Zebrafish 
model, that macrophages can extend protrusions to attach 
and “ferry” tumor-derived EVs towards the cell body before 
engulfing them (Hyenne et al., 2019). The chosen method of 
uptake will undoubtedly reflect the markers present on the 
vesicle surface, although the exact mechanisms for this process 
remain undescribed.
EXTRACELLULAR VESICLES AS 
BIOMARKERS OF CARDIOVASCULAR 
DISEASES
EVs are elevated in patients with a number of conditions, 
including; atherosclerosis (Chironi et al., 2006; Heiss et al., 
2008), deep vein thrombosis or pulmonary embolism (Diehl 
et al., 2001; Rectenwald et al., 2005), cerebrovascular disease (Lee 
et al., 1993; Jung et al., 2009), or in patients exhibiting several 
cardiovascular risk factors such as type-2 diabetes mellitus (Koga 
et al., 2005; Koga et al., 2006), severe hypertension (Preston et al., 
2003), and obesity (Goichot et al., 2006). Uncovering the EV 
parent cell, provides additional and clearer information about 
the pathophysiology of specific cardiovascular diseases (CVDs). 
A small case-control study in the PREDIMED trial of patients 
following a Mediterranean diet observed the concentrations 
of EVs-derived from different cell types. They found that 
participants who suffered a cardiovascular event (CVE) within 
one year of intervention, also presented with elevated EVs 
derived from lymphocytes and smooth muscle cells (SMC) 
compared with unaffected participants (Chiva-Blanch et al., 
2016). Platelet-derived EVs have also been repeatedly described 
as good markers for monitoring CVDs. Indeed, the levels of 
platelet-derived EVs were significantly higher in hypertensive 
patients, who also have diabetes than in non-diabetic patients. 
Similarly, a correlation between plasma, platelets, monocytes, or 
endothelial-derived EVs and hypertensive patients was observed 
in both the presence and absence of diabetes (Nomura et al., 
1995). Another study, showed platelet-derived EVs, but not 
monocyte-derived EVs, could be considered useful biomarkers 
for long term follow-up after a myocardial infarction (MI) 
(Steogonekpień et al., 2012). Increases in endothelial cell (EC)-
derived EVs have also been implicated in many diseases with an 
inflammatory component, such as; atherosclerosis, diabetes, and 
autoimmune conditions. A direct correlation has been reported 
between the numbers of endothelial EC-derived EVs and 
IL-6, indicating a close association with classic inflammatory 
pathways (Ridger et al., 2017).
The improved ability to purify EVs and acquire accurate 
information about their numbers lends itself for the identification 
of new biomarkers, ones that were perhaps previously considered 
too dilute to be accurately quantified. More recent studies have 
exploited this to identify miRNAs with prognostic value for 
CVDs (Zampetaki et al., 2012; Jansen et al., 2014; Kanuri et al., 
2018). Patient serum samples from the METEOR trial were 
tested for the levels of LDL-EVs and their protein content of von 
Willebrand factor (vWF), serpin C1, and plasminogen X. The 
METEOR trial sought to determine the effect of rosuvastatin on 
subclinical atherosclerosis, since patients at risk of CVD with 
high LDL levels, are often treated with statins. The results from 
this trial indicated that rosuvastatin-treated patients, have higher 
levels of plasminogen and vWF in LDL-associated EVs. Serum 
plasminogen levels were also increased but to a lesser extent, while 
serum vWF was unaffected (Verbree-Willemsen et al., 2018). 
Despite the ever-growing literature on EVs, monocyte-derived 
EVs are poorly discussed within the context of cardiovascular 
inflammation, especially considering their presence of tissue 
factor (TF) (Connor et al., 2009; Khaspekova et al., 2016). 
Patients with meningococcal septic shock, who have suffered 
from disseminated intravascular sepsis presented with large 
numbers of monocyte-derived EVs, exposing highly coagulant 
TF. Furthermore, plasma from sickle cell disease patients, was 
reported to contain endothelial and monocyte-derived EVs 
exposing TF, and these EVs were revealed to be procoagulant 
(Shet et al., 2003). In regards to vascular inflammation, Holvoet 
et al. demonstrated that low levels of mitochondrial cytochrome 
oxidase, subunit I in circulating CD14+ EVs were associated with 
a higher risk of developing a new CVE in coronary artery disease 
patients (Holvoet et al., 2016). Also, CD14+ EVs were higher in 
patients with hypertension and with non-ST segment-elevation 
myocardial infarction (NSTEMI) (Christersson, Thulin, and 
Siegbahn 2017). In a prospective single-center cohort study, 
the Athero-Express discovery cohort (1,060 patients), EVs 
containing cystatin C, serpin G1 and F2, and CD14 were 
identified as potential biomarkers of secondary CVE (Kanhai 
et al., 2013). Increased levels of cystatin C, serpin F2, and CD14 
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were associated with an increased risk of MI, vascular events and 
all-cause mortality, whereas increased protein content of CD14+ 
EVs also correlated with a higher risk of an ischemic stroke.
PLATELET-DERIVED EXTRACELLULAR 
VESICLES AS BIOMARKERS OF 
ENDOTHELIAL DYSFUNCTION
Platelet-derived EVs represent the vast majority of EVs in 
circulation and are thought to originate from both circulating 
platelets and platelet precursors, which reside in the bone 
marrow. Although, as we will discuss later, platelet-derived 
EVs are known to play crucial roles in coagulation, thrombosis, 
vascular senescence, and permeability, it has also been 
suggested that circulating platelet-derived EVs can induce 
vascular dysfunction and by immune modulation, can mediate 
thrombotic potency of plasma, inducing remodeling of the 
vasculature. Indeed, elevated levels of platelet-derived EVs 
were described in patients with acute coronary syndrome, MI, 
heparin-induced thrombocytopenia, thrombotic complications, 
and hemolytic uremic syndrome. Whilst abdominal obesity, 
diabetes mellitus, antiphospholipid syndrome, and sepsis 
were not associated with increased circulating levels of these 
EVs (Pinto et al., 2015). In the majority of these studies, it 
has been proposed that platelet adhesion to leukocytes or 
endothelial cells, causes activation and subsequent EV release 
inevitably increasing the inflammatory response (Vagner et al., 
2019). In line with this, platelet-derived EVs were proposed to 
cause dysfunction in arterial hypertension and preeclampsia, 
although the initial triggers for these pathologies were different; 
shear stress and sympathetic activity for hypertension and 
hypoxia/ischemia damage to placental villi for preeclampsia. 
Regardless of these differences, the result in both pathologies 
was platelet activation and a subsequent release of vesicles, 
shown to be the cause of the endothelial dysfunction, vascular 
remodeling, and increased procoagulative state. Platelet-
derived EVs have diagnostic relevance in both hypertension 
and pregnancy for the prediction of endothelial dysfunction. 
Platelet-derived EVs were analysed by ELISA in cohorts of 
pregnant women developing preeclampsia during gestation. The 
results showed an increase, not only in vWF and endothelin-1, 
but also in platelet-derived EVs in these women, which 
suggests EVs represent a valid alternative to already established 
endothelial biomarkers (Vinayagam et al., 2016). Another study 
investigating the interconnection between EVs and arterial 
hypertension, was performed by Preston et al. (2003). Here, 
they measured the abundance of both endothelial and platelet-
derived EVs in patients with untreated severe hypertension 
and mild hypertension compared to normotensive controls. 
The concentration of EVs released from endothelial cells and 
platelets were significantly increased in patients with severe 
arterial hypertension and this correlated strongly with both 
systolic and diastolic blood pressure.
Platelet-derived EVs have also been found to predict several 
complications related to diabetes, another pathology known 
to be strongly associated with endothelial dysfunction and 
the occurrence vascular complications, including; vascular 
endothelial injury and atherosclerosis. Abnormal vascular 
elasticity and flow-mediated endothelial-dependent dilatation 
is demonstrated to occur at the early stage of atherosclerosis 
(Stehouwer et al., 2008). In the context of diabetes, EVs predict 
the development of cardiovascular pathologies associated with 
a loss of artery elasticity and the subsequent development of 
atherosclerotic lesions. As a relevant example, both soluble 
P-selectin and platelet-derived EV levels were significantly 
higher in diabetic patients than healthy controls, especially when 
co-presenting with high levels of LDL (Nomura et al., 1995). The 
role of LDL in initiating and promoting atherosclerosis has been 
demonstrated as early as the 90s (Ross, 1986) and Tschope et 
al., also confirmed that activated platelets play an important 
role in the development of atherosclerosis in patients with 
diabetes (Tschoepe et al., 1993). Taken together, these results 
strengthen the idea that platelet-derived EVs may participate 
in the development and progression of atherosclerosis in 
diabetes mellitus, representing a potential candidate biomarker 
for monitoring these vascular complications. Circulating 
levels of EVs, including annexinV+, platelet, leukocyte, and 
endothelial-derived EVs were measured in 63 patients with type 
2 diabetes and 29 healthy volunteers (Feng et al., 2010). Their 
findings suggest only endothelial-derived EV levels reflect the 
endothelial-dependent vascular dilatation and endothelial 
dysfunction. Platelet-derived EVs positively correlated with 
postprandial blood glucose levels, indicating that postprandial 
glucose-dependent platelet activation, occurred in diabetic 
patients. In line with this, α-glycosidase inhibitor therapy can 
significantly reduce the circulating levels of platelet-derived 
EVs (Shimazu et al., 2009). These findings indicate that acute 
postprandial hyperglycemia in type 2 diabetes may play an 
important role in platelet activation and that platelet-derived 
EVs could therefore represent a novel marker for monitoring 
glucose levels in these patients.
THE ROLE OF EXTRACELLULAR 
VESICLES IN ENDOTHELIAL CELL 
ACTIVATION
ECs represent the first barrier of the vessel wall, protecting 
against pathogen invasion, maintaining vascular integrity and 
are crucial to vascular homeostasis. Perturbations to the vessel 
wall including mechanical injury, or systemic factors such as 
dyslipidemia and smoking can lead EC to alter their phenotype 
causing vascular remodeling. Endothelial cell homeostasis 
operates in a tightly controlled balance, with perturbations to 
this endothelial lining resulting in inappropriate activation and 
a shift towards a pro-inflammatory state; a major contributor to 
vascular pathologies.
Platelets are recruited physiologically to injured vessel walls 
where they become activated and act primarily to prevent 
blood loss however, their inappropriate recruitment to vessel 
walls is a contributing factor of many pathologies, including: 
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thrombus formation, hypertension, atherosclerosis, and stroke 
(Gkaliagkousi et al., 2010; Badimon et al., 2012; Furlan et  al., 
2016). The role of platelets in modulating endothelial cell 
function has been increasingly researched over the years and 
their effects are well described elsewhere (Taraboletti, 1990; 
Hawrylowicz, 1991; Bustos et al., 2001). It is no wonder then, 
that platelet-derived EVs also play a pivotal role in endothelial 
phenotype and function.
The Action of Platelet-Derived 
Extracellular Vesicles on the Endothelium
Platelet-derived EVs are the most abundant type of vesicle found 
in the circulation under basal conditions, accounting for at least 
two-thirds of EVs in circulation (Hunter et al., 2008). The ability 
of platelet-derived EVs to induce increases in surface activation 
on the endothelium is well-reported, including elevation of 
the adhesion molecule ICAM-1 (Nomura, 2001; Gidlöf et al., 
2013), an effect later ascribed to miR-320b transfer (Gidlöf et al., 
2013). Platelet-derived EVs also induce increases in EC cytokine 
production; IL-8, IL-1, and IL-6, reiterating their enhanced state 
of activation (Nomura, 2001) (Figure 2). Platelet-derived EVs 
may also facilitate in the destruction of vascular and immune 
cells in immunoreactive vascular conditions such as immune 
thrombocytopenia, in which platelets are routinely targeted for 
removal by the immune system (Cines and McMillan, 2005). 
Platelet-derived antigens such as HPA-1a can be transferred to 
endothelial and monocytic cells (THP-1), that readily react with 
HPA-1a positive antibodies. In this way, these EVs could be 
responsible for spreading the potential target cell population for 
autoreactive responses (Majka et al., 2007).
Despite being anucleate, many of the purported effects of 
platelet-derived EVs can be linked to the delivery of miRNAs. 
Platelets are now acknowledged to contain approximately 220 
different miRNAs (Landry et al., 2009; Kannan et al., 2009) 
and these can be actively transported to endothelial cells via 
EVs. For example, miR-223 was delivered to EC via platelet-
derived EVs, resulting in a 22-fold increase in HUVEC miR-
223, which was sustained for 48 h (Laffont et al., 2013; Pan et al., 
2014). The biological property of EVs to act as intercellular 
carriers of functional microRNAs has been reiterated by many 
other groups. Bao et al. reported miR-142-3p; which they 
detected as the most highly expressed microRNA in platelets, 
could be transferred to EC via platelet-derived EVs but not by 
platelets themselves (Bao et al., 2017). miR-142-3p suppressed 
the expression of target gene BCL2L1 and BCL2-associated 
transcription factor (BCLAF1) (Bao et al., 2017; Bao et al., 2018), 
resulting in increased proliferation and EC apoptosis in an in 
vivo rat model of hypertension. Upregulated EC proliferation and 
apoptosis play crucial roles in vascular remodeling associated 
with hypertension (Bao et al., 2017; Bao et al., 2018). In the 
same vein, the addition of stimulated platelet-derived miR-223 
via EVs, resulted in a reduction of insulin-like growth factor-1 
receptor with subsequent promotion of HUVEC apoptosis, 
triggered by advanced glycation end products (Pan et al., 2014). 
This microRNA was found to be elevated in mice with high-fat 
FIGURE 2 | Extracellular vesicles promote endothelial cell activation. Schematic representation of the potential role of in vitro-generated extracellular vesicles (EVs), 
focusing mainly on the role of EVs in vascular inflammation, thrombosis, and regulation of endothelial function. Vesicles of platelet origin can stimulate endothelial 
cells and leukocytes depending on their cargo of proteins, lipids, and non-coding RNAs. The presence of the microRNAs; miR-223 and miR-142-3p in platelet EVs 
is important in regulating both proliferation and apoptosis of endothelial cells. In addition, miR-320b can stimulate expression of ICAM-1, while lipid transfer can 
regulate COX-2 activation. Platelet EVs also increase the release of several cytokines. EVs of platelet origin also promote monocyte inflammation, and together with 
leukocyte-derived vesicles, favor thrombosis. Monocyte EVs are responsible for activating NF-kB pathway in endothelial cells and enhance expression of selectins, 
integrins, adhesion molecules, as well as the release of cytokines. Presence of active TF in monocyte EVs also increases thrombosis, while presence of IL-1β, 
caspase-1, and NLRP-3 induces endothelial apoptosis. EVs released by monocytes promote endothelial inflammation by increasing leukocyte adhesion through 
the release of several miRNAs. Finally, neutrophil-derived EVs were found to express selectins, integrins, Mac-1, and LFA-1 and are able to enhance endothelial 
expression of ICAM-1 and release of IL-6 and IL-8. AA, Arachidonic acid; CCL5, C-C motif chemokine 5 (also known as RANTES); COX-2, cyclooxygenase type 2; 
ICAM-1, intercellular adhesion molecule 1; LFA-1, leukocyte function-associated antigen 1; NO, nitric oxide; PGI2; P-Sel, P-selectin; PtdSer, phosphatidylserine; TF, 
tissue factor; TLR-4/D88, toll like receptor 4; CP, ceruloplasmin.
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diet induced atherosclerotic lesions and was elevated in both 
circulating platelets and platelet-derived EVs in atherosclerosis, 
hepatitis, enteritis, or nephritis patients (Pan et al., 2014).
Platelets not only contain miRNA, but also the machinery to 
process pre-miRNA; Dicer, AGO2, and RNA-binding protein 
2 (Landry et al., 2009; Laffont et al., 2013), indicating that they 
are capable of processing pre-miRNA (Warshaw et al., 1967). 
Unlike leukocyte derived-EVs, platelet-derived EVs possess 
elevated levels of pre-miRNAs and mature miRNA. Within 
platelet-derived EVs the concentration of mature miRNA could 
be enhanced following stimulation with thrombopoietin (Pan 
et al., 2014). This finding further confirms that platelets are 
able to convert pre-miRNA into a mature form, which can be 
actively packaged into vesicles for release. Depending on the 
method of stimulation, platelets were preferentially depleted of 
specific miRNAs, leading to the generation of platelet-derived 
EVs, enhanced in key platelet-miRNAs. Platelets recovered from 
patient thrombi were depleted of miR-22, much more so than 
in those recovered from experimentally induced aggregation 
(Gidlöf et al., 2013). How specific contents are packaged and 
become enriched in EVs is still unknown, although perhaps 
activation and therefore upregulated production of these contents 
is sufficient to cause this seemingly selective packaging.
EVs are an abundant source of lipids, as such, their delivery can 
regulate lipid metabolism in recipient cells. Platelet-derived EVs 
are able to initiate lipid metabolism in EC and in platelets through 
the transport of arachidonic acid (AA). In HUVEC, receiving 
AA from platelet-derived EVs induced cyclooxygenase-2 (COX-
2) activity, resulting in the subsequent generation of prostacyclin 
(PGI2) (Barry et al., 1999), which is known to limit platelet 
activation and leukocyte recruitment. The initiation of lipid 
metabolism was also investigated in preeclamptic women. In this 
case, their EV profiles displayed pro-inflammatory properties; 
inducing vascular hyporeactivity in vessels of both humans and 
mice. These effects were also found to be related to interactions 
between NO and cyclooxygenase systems, leading to endothelial 
cell activation (Cines and McMillan, 2005).
Platelet-Derived EVs Modulate Leukocyte 
Interactions with the Endothelium
Platelets have the ability to interact with other leukocytes 
in circulation and can affect the way they interact with the 
endothelium. There are a number of ways by which platelet-
derived EVs can alter the adhesiveness of recipient cells and 
influence their interactions with the endothelium. Firstly, it can 
be initiated through providing functional P-selectin expressed 
on the platelet-EV surface, this was demonstrated by Forlow and 
colleagues (Forlow et al., 2000). Secondary adhesion to vessel 
walls (leukocytes adhering to other leukocytes already rolling on 
an endothelial surface), requires interactions mediated through 
L-selectin. L-selectin interactions induce a rolling state that is 
faster and more transient than interactions provided by other 
selectin members (Forlow et al., 2000). The threshold shear stress 
that is required to optimally support these bonds can be bridged 
by platelet-derived EVs deposited on the endothelium. These 
allow maximal tethering of neutrophil-neutrophil interactions by 
providing P-selectin at a lower shear requirement (Forlow et al., 
2000). Given that plasma platelet-derived EV concentrations 
are elevated in cardiovascular conditions and that physiological 
concentrations of platelet-derived EVs do not significantly affect 
endothelial activation, it would suggest that platelet-derived EVs 
may contribute to increased leukocyte aggregation and adhesion 
on vessel walls during pathology.
Another mechanism of platelet-derived EV induced 
adhesiveness occurs by modulating the expression of adhesion 
molecules. Platelet-derived EVs can upregulate the expression 
of CD11b and ICAM-1 on THP-1 monocytic cell lines and EC 
respectively, resulting in increased adhesion between these two 
cell types. This was observed alongside increases in cytokine 
transcription and translation from both cells; including IL-8 
and IL-1 β (Nomura, 2001). In fact, platelet-derived EVs may 
also directly deliver IL-1 β to EC, therefore increasing the 
adhesiveness of neutrophils to endothelial cells (Lindemann 
et al., 2001). Other groups have reported the upregulation of 
adhesion molecules lymphocyte function-associated antigen-1 
LFA-1 (CD11a/CD18) and macrophage antigen-1 Mac-1 
(CD11b/CD18) on monocytic cells (Barry et al., 1997). One 
proposed mechanism of platelet derived-EV mediated activation, 
is through the delivery of AA acting through protein kinase C 
(PKC) (Barry et al., 1997). A recent paper showed platelet-
derived EVs potentiated neutrophil capture under flow, although 
these interactions were predominantly modulated through 
P-selectin and integrins (Kuravi et al., 2019). The addition of 
platelet-derived EVs can also directly recruit immune cells, 
through the deposition of functional chemokines such as CCL5 
(RANTES) to endothelial membranes. CCL5 deposition was 
found to require a number of receptors on the surface of platelet-
derived EVs including sJAM-A and GPIIb/IIIa Fab-fragment, 
all working in concert (Mause et al., 2005). Increased activation 
and aggregation of leukocytes on the endothelial vessel wall may 
potentiate extravasation and inappropriate activation of vessels, 
contributing to vascular inflammatory disorders. As previously 
mentioned, lipids play a significant role in modulating the effects 
of EVs and again, AA from platelet-derived EVs was found to 
induce eicosanoid formation in monocytic cell lines (U-937) 
through the induction of COX-2 and corresponded to the 
increased synthesis of prostaglandin E2 and thromboxane B2. 
This required PKC signaling, PI 3-kinase, p42 and p44 MAPK, 
and P38 kinase enzyme abilities (Barry et al., 1997).
Monocyte-Derived Extracellular Vesicles 
Activate the Endothelium
Levels of circulating leukocyte-derived EVs are typically low, but 
do rise precluding an acute or systemic inflammation. The role 
of activated monocytic-derived EVs on the endothelium was 
explored by Wang et al. (2011). LPS stimulated THP-1 derived 
MVs, but not those from unstimulated cells, were able to bind 
HUVEC and were subsequently internalised, localizing with the 
EC cytoplasm. This mechanism has previously been suggested to 
be dependent on CD18a/LFA-1 interactions (Aharon et al., 2008). 
LPS-induced THP-1-derived MVs, once internalised, induced 
ERK1/2 and NF-κB signaling pathways as well as the expression 
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of NF-κβ-dependent genes; VCAM-1, ICAM-1 and E-selectin. 
Active IL-1 b could be detected in these LPS stimulated THP-1-
derived MVs, but was undetectable in MVs from untreated cells. 
In accordance with this, higher levels of NLRP3 and caspase-1 
were also reported, in this way active inflammasome could initiate 
inflammatory responses in otherwise resting cells (Figure 2). 
Histological observations indicated that EC incubated with THP-
1-derived MVs developed an elongated cellular morphology 
and gaps appeared between cells after a 20 h incubation. High 
doses of MVs; 50 μg, resulted in a sharp increase in apoptosis 
of EC, whist lower doses of 10 μg had little effect (Aharon et al., 
2008). Monocyte derived-EV induced EC death has also been 
described in human pulmonary microvascular endothelial cells 
(HPMVEC). These EVs contained the active caspase-1 (p20) and 
induced cell death only when the parent cell was stimulated with 
LPS, but not under basal conditions. Inhibition of caspase-1 and 
active caspase-1 was efficient at abrogating these effects (Mitra 
et al., 2015).
It is pertinent to acknowledge the ability of monocyte-derived 
EVs to increase thrombogenicity of EC. This occurs initially due 
to the presence of monocyte-derived EVs increasing exposure 
of PtdSer on the EC surface. PtdSer acts as a binding site for 
members of the coagulation pathway, including prothrombinase, 
TF/VIIa, and tenase. Secondly, increased thrombogenicity 
occurs through the transfer of TF from monocyte-derived EVs to 
EC. Interestingly, TF is expressed at higher levels on monocytic-
derived EVs, than on monocytes themselves (Aharon et al., 
2008). Endothelial TF mRNA expression was also upregulated 
following coincubation with monocyte-derived EVs—indicating 
that intervesicular cargo modulated signaling processes to 
contribute to thrombotic effects exerted by EC (Aharon et al., 
2008). Similarly, these EVs also reduced the anticoagulant tissue 
factor pathway inhibitor and thrombomodulin in EC (Aharon 
et al., 2008). At an intrinsic level, EVs could therefore play a role 
in vascular inflammation in hypercoagulable states. Moreover, 
high glucose was demonstrated to induce EV release from 
THP-1 cells with functionally intact TF. Mechanistically, both 
the ERK/MAPK and p38/MAPK pathway were activated after 
high glucose stimulation, whereas treatment with a p38 inhibitor 
decreased EV generation by 66% (compared to untreated 
controls), suggesting a role for p38/MAPK pathway components 
in regulating the release of monocyte-derived EVs in the context 
of diabetes (Li et al., 2017). Increased apoptosis of endothelial 
cells and thrombogenicity, is a hallmark of a number of vascular 
diseases and is a significant event during atherosclerotic plaque 
formation (Morel et al., 2006). Monocyte-derived EVs are 
attributed other interesting properties, such as tube formation 
when EC were seeded on Matrigel, initiating pro-angiogenic 
effects (Kim et al., 2004; Aharon et al., 2008).
Intervesicular cargo, specifically miRNA plays a considerable 
role in the effector functions of membrane bound vesicles. In fact, 
Dalvi et al., reported monocyte-derived exosomes alter miRNA 
profile in human brain microvascular endothelial cells (HBMEC). 
The major constituents of the blood brain barrier; increased miR-
146a, miR-146b, miR-155, mir-125a-5p and decreased miR-222 
resulting in the induction of inflammatory pathways via the 
TLR4/D88 pathway (Dalvi et al., 2017) (Figure 2). It has also 
been shown that distinct EV miRNA profiles can be generated 
when monocytes were stimulated with endotoxins and cytokines, 
which can activate HBMV and upregulate their expression of 
ICAM-1, VCAM-1, CCL2, and the pro-inflammatory cytokines 
IL-1β and IL-6, even encouraging monocyte migration. In this 
way, monocyte-derived EVs may contribute to an inflammatory 
milieu, disrupting the blood brain barrier and allowing immune 
cell infiltration; a significant component of many conditions 
including Alzheimer’s disease, multiple sclerosis, and stroke 
(Banks et al., 2015).
Pro-inflammatory profiles; ICAM-1, CCL2, and IL-6 
expression, can be induced when primary monocyte-derived 
exosomes are incubated with HUVEC. This effect required 
NF-κB signaling. Interestingly, IFN-induced monocyte-derived 
exosomes upregulated the expression of NF-κB but without 
activation, unlike the generation of exosomes from LPS which 
showed significant activation (Tang et al., 2016). Cytoplasmic 
NF-κB could therefore act as a reservoir, allowing its rapid 
release following additional stimuli, this phenomena has been 
previously described during macrophage differentiation (Conti 
et al., 1997). Here we are reminded of the distinct EV profiles that 
can be generated from a single cellular source. Indeed LPS/Ca2+ 
ionophore-induced monocyte-derived EVs, presented higher 
expression levels of Tsg101, whilst low endosomal markers were 
found in EVs obtained after 20 h starvation (Aharon et al., 2008).
In contrast to membrane derived EVs, intraluminal monocyte-
derived exosomes were found to maintain their size and generation 
rate, even in the presence of stimulation. Their contents however, 
were considerably different (Tang et al., 2016). Monocyte-derived 
exosomal miRNA content was significantly altered with IFN or 
LPS stimulation, with significant increases in miR-155, alongside 
reductions in miR-223 when compared to exosomes generated 
from non-stimulated cells (Tang et al., 2016) (Figure 2). miR-
155 has most recently been ascribed pro-inflammatory effects: 
elevating the expression of pro-inflammatory genes, activating 
NF-κB, promoting atherosclerosis and foam cell formation (Ma 
et al., 2011; Bala et al., 2011; Nazari-Jahantigh et al., 2012; Tian 
et al., 2014). There are conflicting reports on the role of miR-223 
in the literature, as previously discussed, platelet-derived miR-
223 resulted in reduced insulin-like growth factor-1 receptor 
and the promotion of apoptosis. It has also been implicated in 
high-fat diet induced atherosclerotic lesions in in vivo models 
and in patients with atherosclerosis and hepatitis (Pan et al., 
2014). However, miR-223 has also been reported to reduce 
IL-6 and IL-1 β generation in macrophages (Chen et al., 2012), 
downregulate ICAM-1 (Tabet et al., 2014) and to have anti-
inflammatory and cardioprotective effects (Barwari et al., 2016). 
In this report, decreases in miR-223 alongside increases in miR-
155 correlated with increased endothelial cell activation (Tang et 
al., 2016). It is likely that gene regulation, along with many other 
exosomal contents and surface molecules, determine the overall 
fate of cell activation. Despite the conflicting reports on miRNA 
involvement, it seems exosomes released from monocytes with 
an activated phenotype could therefore potentiate inflammation 
under pathological settings. Monocyte-derived EVs have also 
been implicated in reactive oxygen species (ROS) generation 
and signaling. Apoptotic THP-1-derived EVs (generated from 
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etoposide incubation for 24 h) were shown to increase nitric 
oxide (NO) production in endothelial cells in in vitro models, 
although iNOS and superoxide were not affected by EV treatment 
(Mastronardi et al., 2011). Given that ROS can cause cell damage 
and dysfunction, the data indicate monocyte-derived EVs can 
have detrimental effects on endothelial physiology.
Neutrophil-Derived Extracellular Vesicles 
Exert Direct Endothelial Actions
Neutrophil-derived EVs appear to share many similarities 
with monocyte-derived EVs with respect to their effects on the 
endothelium, although they are less explored than monocyte-
derived EVs. Mersi and Altieri in 1998 were the first to investigate 
this. Neutrophil and EC co-cultures resulted in net increases 
of the pro-inflammatory cytokines IL-6 and IL-8; a 35-fold 
increase on the response elicited from each cell type cultured 
alone (Mesri and Altieri, 1998). Neutrophil-derived EVs were 
able to indistinguishably replicate the IL-6 response observed 
in EC, which was unaffected by the presence of a soluble IL-6R 
inhibitor. Characterisation of neutrophil-derived EVs revealed 
the expression of a host of surface proteins including selectins, 
integrins; LFA-1/CD11a, Mac-1/CD11b, and CD62L (L-selectin) 
as well as regulators of complement; MCP/CD46 and CD59 
(Gasser et al., 2003) (Figure 2). Neutrophil-derived EVs were 
found to bind to THP-1 cells and HUVEC in a dose-dependent 
manner, but were unable to bind erythrocytes, indicating these 
interactions were receptor mediated.
The majority of studies investigating neutrophil-derived EV 
actions on EC appear to be centered around activation. Anti-
neutrophil cytoplasmic antibodies (ANCAs) are autoantibodies 
directed against neutrophil antigens and are associated with rare 
and often fatal conditions called ANCA-associated vasculitis. 
Elevated levels of EVs are reported in ANCA-associated vasculitis 
and in patients with active vasculitis (Brogan et al., 2004; 
Daniel et al., 2006; Erdbruegger et al., 2008; Clarke et al., 2010), 
specifically CD66b+ EVs (Daniel et al., 2006). Hong et al. revealed 
that stimulating cytokine-primed neutrophils with ANCAs, but 
not resting neutrophils generated EVs that were phenotypically 
distinct from those released under basal conditions (Hong et al., 
2012). ANCA significantly increased EV generation compared to 
controls and displayed elevated markers of activation including 
functionally active CD11b/CD18, myeloperoxidase (MPO) and 
importantly, ANCA autoantigens. These EVs were able to bind the 
endothelium, an interaction dependent on β2 integrin CD18 and 
induced the production of IL-6 and IL-8 in EC. This endothelial 
activation was not merely dependent on the sheer increase in EV 
quantity, but also due to distinct content and surface expression 
as increasing concentrations of resting neutrophil-derived EVs 
did not affect the endothelium. This research reiterates that the 
quantity of EVs as a biomarker, may not be sufficient but rather the 
quality or constituents of these EVs. Similarly, ANCA-stimulated 
supernatants upregulated endothelial ICAM-1 surface expression 
due to increased oxidative stress, as indicated by abrogated effects 
in the presence of antioxidants. Wang et al. revealed independent 
thrombin generation abilities of neutrophil derived-EVs, which 
was not exhibited by EVs from resting neutrophils (Wang et al., 
2011). ANCA stimulated neutrophil derived-EVs present the 
potential missing link between how ANCAs can bind EC, despite 
an EC lacking the respective autoantigens.
Leukocyte-Derived Extracellular Vesicles 
Modulate Leukocyte-Endothelial 
Interactions
Leukocyte-derived EVs are also able to influence other cells in the 
circulation and affect the way they interact with the endothelium. 
Our group have previously reported anti-inflammatory and pro-
resolutive properties of neutrophil-derived EVs on leukocyte-
endothelial interactions. Dalli et al. reported significantly 
reduced neutrophil recruitment and adhesion to endothelial cell 
monolayers, when cells were pre-incubated with fMLP generated 
neutrophil-derived EVs (Dalli et al., 2008) (Figure 2). These EVs 
contained the anti-inflammatory protein Annexin-A1 (AnxA1) 
and these effects were lost in the presence of a neutralising 
antibody against AnxA1 or against the AnxA1 receptor; Lipoxin 
A4 receptor ALX. This anti-inflammatory action was also observed 
in an in vivo air pouch model, where neutrophil recruitment was 
markedly reduced, again dependent on the action of AnxA1; as 
WT neutrophil-derived EVs, but not those from AnxA1 null 
mice were able to elicit a reduction in neutrophil infiltration. 
In this way, neutrophil-derived EVs act in an autocrine manner 
to dampen immune activation and promote resolution. This is 
not the only report of protective neutrophil-derived EVs as they 
are shown to significantly dampen pro-inflammatory cytokine 
release from monocytes (Gasser and Schifferli, 2004).
A recent paper revealed divergent effects of exosomes in in 
vitro-exosome mixtures from both HUVEC and monocytic cells 
generated under high glucose conditions increased ICAM-1 
expression on both cell types. However, exosomes generated 
under basal-conditions from both cell types were able to reverse 
the high-glucose activation of ICAM-1 (Sáez et al., 2019). Indeed, 
monocyte-derived EVs increased transient platelet attachment to 
HUVEC under flow; in part through upregulated vWF expression 
resulting from the increased generation of ROS; predominantly 
superoxide (Essayagh et al., 2007). Monocyte/macrophage EVs 
also accelerate the development of atherosclerosis by decreasing 
cell migration and promoting macrophage entrapment in the 
vessel wall via delivery of specific miRNAs, e.g. miR-146a 
(Nguyen et al., 2018).
EXTRACELLULAR VESICLES PROMOTE 
ENDOTHELIAL DYSFUNCTION AT THE 
CELLULAR AND TISSUE LEVEL
It is important to highlight how subsets of EVs may influence 
pathological vascular processes, acting not only on EC, but 
also on other blood components involved in the development 
of these pathologies. In line with this, a few studies focusing 
on atherothrombosis have investigated the role of monocyte-
derived EVs and neutrophil-derived EVs in the activation of 
macrophages; well known to be crucial during plaque formation. 
Currently, the data regarding monocyte/macrophage-derived EVs 
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collectively suggests a pro-inflammatory role on macrophages, 
inducing: superoxide anion production, pro-inflammatory 
cytokine release, NF-κB activation (Bardelli et al., 2012) and 
apoptosis (Sarkar et al., 2009). Neutrophil-derived EVs were able 
to block the inflammatory responses of macrophages to zymosan 
and LPS, due to early-phase TGF-β1 secretion and the surface 
exposure of PtdSer (Gasser and Schifferli, 2004).
Leukocyte- derived EVs have also been shown to activate 
SMC. For example, monocyte-derived EVs containing caspase-1 
isolated from endotoxin treated cells, were able to induce apoptosis 
in VSMC. This activity was not derived from pre-treatment with 
endotoxin, and was inhibited by a caspase-1 inhibitor, but not 
by inhibitors of Fas-L, IL-1β and IL-18. Moreover, caspase-1 
encapsulation was required to guarantee the effect, as disruption 
of EV structure resulted in the loss of apoptotic activity, but not of 
caspase-1 enzymatic activity. Thus, monocytes were demonstrated 
to deliver their cell-death message, dependent upon the release 
of EVs containing functional caspase-1. Similarly, neutrophil-
derived EVs isolated from cells that had been stimulated with 
LPS could modulate the phenotype of airway SMC in the context 
of asthma. Briefly, the authors showed the ability of neutrophil-
derived EVs to be rapidly internalised by airway SMC and to alter 
their proliferative capacity, highlighting their potential important 
role in the progression of asthma and airway remodeling (Vargas 
et al., 2016). Beside leukocyte-derived EVs platelet-derived EVs 
were described to be responsible for skewing smooth muscle cells 
from a contractile, to a synthetic phenotype (Vajen et al., 2017).
EVs also contribute to several vascular pro-inflammatory 
events at the tissue level. Subsets of EVs are well recognised 
for their ability to promote coagulation and thrombosis. The 
production of EVs leads to the surface expression of anionic 
phospholipids; mainly PtdSer, which enhances their pro-
coagulant activity. Indeed, the externalised negatively charged 
phospholipids contribute to the assembly and the activation of 
prothrombinase complexes, thus enhancing thrombin formation 
(Owens and Mackman, 2011). Although PtdSer is exposed on the 
surface of most EVs, particularly those of platelet origin (Italiano 
et al., 2010; Flaumenhaft et al., 2010), EVs that stain negatively for 
annexin V have also been described, demonstrating the existence 
of PtdSer-negative EV populations. This would indicate the 
existence of other molecules, expressed by EVs also contribute to 
their pro-thrombotic role (Perez-Pujol et al., 2007).
The procoagulant activity of different subsets of EVs is 
further increased by the expression of TF and EVs that bear 
both PtdSer and TF, have the highest procoagulant activity. TF 
is a key modulator of the coagulation cascade; its extracellular 
domain binds and activates factor VII, triggering hemostasis 
after vascular injury. Interestingly, monocyte-derived EVs 
are the main source of TF in the blood stream. Several studies 
have shown the stimulation of monocytes with different pro-
inflammatory stimuli, such as angiotensin II or IL-33, enhances 
EV release and pro-coagulant features (Cordazzo et al., 2013). 
They also induce a time and concentration-dependent increase 
in monocyte TF mRNA and protein levels via binding to the 
ST2-receptor and activation of the NF-κB-pathway (Stojkovic 
et al., 2017). Moreover, the interaction of the endothelium with EVs 
isolated from monocytes, results in overexpression of TF on the 
EC surface and a reduction in expression of the anticoagulant 
tissue factor pathway inhibitor (TFPI) and thrombomodulin 
(TM), suggesting that monocyte-derived EVs can themselves 
increase endothelial thrombogenicity. Although to a lesser extent, 
EVs isolated from platelets, granulocytes and endothelial cells 
were also able to exert high TF activity (Shustova et al., 2017). 
EC-derived EVs demonstrated the ability to induce TF expression 
and to increase the procoagulant activity of THP-1 monocytic 
cells (Sabatier et al., 2002). Circulating EVs additionally 
contribute to thrombosis through indirect mechanisms that 
are not associated with either TF or PtdSer surface expression. 
The use of Badimon perfusion chambers revealed EVs isolated 
from healthy blood volunteers, significantly enhanced platelet 
deposition on damaged arteries (Suades et al., 2012). Similarly, 
blood enriched with platelet-derived EVs, induced fibrin 
deposition on human atherosclerotic arteries and platelet 
adhesion to collagen-coated surfaces. Epinephrine/collagen 
closure time (critical in plaque formation) was significantly 
reduced with the addition of platelet-derived EVs, along with 
increased platelet aggregation in response to low doses of ADP 
and reduced clotting time. All together these results suggest that 
platelet-derived EVs, even under physiological conditions, can 
induce platelet activation and subsequent thrombus formation 
(Suades et al., 2012). EVs released from activated platelets may 
then, in turn, enhance the activation of non-activated circulating 
platelets and the endothelium (Barry et al., 1997).
In the last decade, a number of studies have demonstrated 
the role of EVs in angiogenesis and highlighted their therapeutic 
potential. Angiogenesis is a dynamic and heavily regulated 
process in which EC are in constant communication with their 
environment through multiple paracrine factors. EVs have the 
ability to induce angiogenesis, through the delivery of their 
specific cargo. As a relevant example, EVs mediated the transfer 
of miR-150 from monocytes to EC, and induced angiogenesis in 
these cells. Secreted miR-150 from THP-1-derived EVs entered 
EC and enhanced migration and tube formation. Moreover, they 
found that miR-150-containing EVs collected from the plasma of 
atherosclerotic patients enhanced angiogenesis in vivo (J. Li et al., 
2013a). Besides monocyte-derived EVs, platelet-derived EVs also 
contributed to angiogenesis by way of cellular activation. This 
role was first described in 2004. Platelet-derived EVs isolated 
from healthy donors promoted proliferation, migration and tube 
formation of HUVEC through the cooperative effect of VEGF, 
FGF-2 and lipid components such as sphingosine-1-phosphate 
(Kim et al., 2004). Downstream signaling mechanisms involved 
in these effects were; the pertussis toxin-sensitive G protein and 
the PI3 kinase pathway. The proangiogenic activity of platelet-
derived EVs was further supported by a variety of other studies. 
Platelet-derived EVs from Crohn’s Disease patients increased 
angiogenesis in a VEGF, FGF-2 dependent manner122. Platelet-
derived EVs were also shown to be proangiogenic in an in vivo 
rat aortic ring model, due to the transfer of growth factors, such 
as VEGF, FGF-2 and PDGF; was dependent on PI3 kinase, src 
kinase, and ERK signaling events. Additionally, in a model 
of chronic myocardial ischemia in rats, platelet-derived EVs 
increased the formation of functional capillaries after injection 
into the myocardium (Brill et al., 2005). Platelet-derived EVs 
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enhanced tumor progression and angiogenesis in a mouse 
lung cancer model, through the upregulation of factors 
associated with tumor vascularisation, such as IL-8, VEGF, 
and HGF (hepatocyte growth factor) (Janowska-Wieczorek 
et al., 2005). Recently, Sun et al., showed these EVs were able 
to promote HUVEC capillary-like network formation and 
migration in a dose-dependent manner. Moreover, levels of 
metalloprotease expression and activity; mostly MMP-2 and 
MMP-9, were upregulated in HUVEC. These pro-angiogenic 
and pro-migratory effects were abolished with the inhibition of 
MMPs (Sun et al., 2017). Angiogenesis can also be regulated by 
lymphocyte-derived EVs. These EVs strongly suppressed aortic 
ring microvessel sprouting and corneal neovascularisation. 
Moreover, they considerably diminished HUVEC survival and 
proliferation in a concentration-dependent manner in vitro, 
by augmenting ROS generation via NOX and interfering with 
the VEGF signaling pathway (Yang et al., 2008). Additionally, 
neutrophil-derived EVs play an active role in maintaining vessel 
integrity. Deposition of EVs during neutrophil extravasation was 
essential for maintaining endothelial barrier function during 
vascular inflammation (Lim et al., 2013). On the other hand, a 
recent study highlighted the involvement of neutrophil-derived 
EVs in atherogenesis, contributing to the plaque formation and 
progression by releasing miRNAs (Gomez et al., 2015).
EXTRACELLULAR VESICLES IN 
VASCULAR INFLAMMATION
It is not surprising that the role of EVs in vascular inflammation 
and in mediating vascular disease has been extensively 
investigated, with the most studied being platelet-derived 
EVs. Platelet-derived EVs carry similar, but not identical 
surface repertoire compared to their parent cells and can exert 
immunomodulatory effects on distant target cells (Varon and 
Shai, 2015). Several components such as growth factors (platelet-
derived growth factor, TGF-β), enzymes (12-lipoxygenase, 
thromboxane synthase), cytokines e.g. IL-1, transcription 
factors and even functional mitochondria are found in platelet-
derived EVs and can be efficiently internalised by other cells 
such as EC, macrophages, and neutrophils (Pierce, 1989; Brown 
and McIntyre 2011; Laffont et al., 2013; Boudreau et al., 2014; 
Duchez et al., 2015; Laffont et al., 2016). Different mechanisms of 
internalisation are described for different cell types. For example, 
EC recognize PtdSer by receptors such as developmental 
endothelial locus-1 (Del-1) and the interaction of the receptor 
tyrosine kinase Axl with its ligand Gas6 found on the surface of 
EVs (Dasgupta et al., 2009; Happonen et al., 2016). The uptake 
by neutrophils seems reliant on 12-lipoxygenase activity present 
within EVs (Duchez et al., 2015). 12-lipoxygenase ablation 
prevents the internalisation of platelet-derived EVs within 
the arthritic joint and consistently decreases inflammation. 
Recently, another study showed the immunomodulatory role 
of platelet-derived EVs on CD4+ T cells during atherosclerosis 
(Sadallah et al., 2014). Moreover, platelet-derived EVs also 
harbor growth factors such as VEGF, FGF-2 and lipid factors, 
suggesting these vesicles may regulate angiogenesis (Brill et al., 
2005). As previously mentioned, platelet-derived EVs have the 
interesting ability of enhancing cellular migration, proliferation, 
survival and tube formation in HUVEC, whilst concurrently 
reducing apoptosis (Kim et al., 2004). Platelet-derived EVs also 
increased the pro-angiogenic MMP-2 and MMP-9 in EC both 
in vitro and in vivo (Kim et al., 2004). Beyond their usefulness 
as possible markers of platelet activation, platelet-derived EVs 
have exhibited a plethora of properties that can be related 
to atherothrombotic disease, such as enhancing platelet and 
fibrin deposition on atherosclerotic arterial wall, promoting 
platelet adhesion, enhancing the recruitment of leukocytes and 
thrombus formation (Suades et al., 2012). Other important 
subsets of EVs have also been described as promoters of 
vascular inflammation. Neutrophil-derived EVs are implicated 
as triggers of atherosclerosis through the delivery of miR-155 
to atheroprone endothelium and enhancing NF-κB expression 
(Gomez et al., 2018).
Endothelial-derived EVs were recently reviewed as a causative 
agent in vascular pathologies. They carry many proteins derived 
from their surface such as adhesion molecules: VE-cadherin, 
platelet endothelial cell adhesion molecule 1, ICAM-1, E-selectin, 
α-integrin, growth factors; endoglin, CD146, VEGF receptor, 
and hemostatic molecules; vWF, TF, TFPI, tissue plasminogen 
activator, plasminogen activator inhibitor 1, endothelial protein 
C receptor (EPCR). They also contain active components such 
as, endothelial NO synthase and urokinase type plasminogen 
activator (Dignat-George and Boulanger, 2011). The circulating 
levels of endothelial-derived EVs are thought to represent 
a balance between cell stimulation, proliferation, apoptosis 
and necroptosis. A number of different pro-inflammatory 
or coagulation stimuli, can increase their presence such as; 
TNF-α, LPS, ROS, plasminogen activator inhibitor, thrombin, 
camptothecin, C-reactive protein, uremic toxins, and estrogens 
(Brodsky et al., 2002; Šimák et al., 2002; Faure et al., 2006; 
Szotowski et al., 2007). Recently, endogenous NO and oxidised 
lipids (Nomura et al., 2004), were shown to enhance endothelial-
derived EVs release coinciding with increased mechanical stress 
(especially shear stress), which could be an initiating event 
in endothelial dysfunction. Moreover, the expression of TF 
on endothelial-derived EVs could be induced (Kagawa et al., 
1998; Combes et al., 1999; Šimák et al., 2002). With regards to 
vascular homeostasis, the expression of anionic phospholipids, 
especially PtdSer, contributes to their procoagulant role (Owens 
and Mackman, 2011). Endothelial-derived EVs can also 
bind monocytes, activate them and consequently induce TF 
expression (Combes et al., 1999). Conversely, a variety of studies 
have shown endothelial-derived EVs exhibit anticoagulant and 
vasculoprotective potential. They were able to deliver miR-126 
or TXA2 to the vessel wall (Mostefai et al., 2008) and can express 
endothelial protein C receptor (EPCR) and activated protein 
C (APC); reported to have anticoagulant and cytoprotective 
effects by reducing apoptosis (Morel et al., 2009). Furthermore, 
endothelial-derived EVs can catalyse the generation of plasmin 
by plasminogen, which would support clot dissolution through 
increased fibrinolysis properties (Lacroix et al., 2007). In line with 
these divergent roles for endothelial-derived EVs, angiogenic 
properties have also been associated with endothelial-derived 
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EVs, in this case concerning its impairment. LDLR-/- mice on high 
fat diet were injected with both pathological and physiological 
concentration of endothelial-derived EVs, which reduced the 
activity of nitric oxide synthase, NO release, and angiogenesis 
(Ou et al., 2011). This inhibitory effect of EVs on vessel formation 
was also shown in diabetic patients with coronary artery disease 
(Tsimerman et al., 2011). Nevertheless, endothelial-derived 
EVs from HBMEC were found to promote angiogenesis at 
low concentration, through plasmin generation, whereas 
higher concentrations had the opposite effect (Lacroix et  al., 
2007). Perhaps the differing purported effects for endothelial-
derived EVs on vessel formation, could be dependent on the 
concentration in each of the different models.
EVS IN TISSUE RESOLUTION AND REPAIR
The inflammatory process develops along three sequential 
and overlapping phases: inflammation, resolution, and repair 
(Headland and Norling, 2015). For decades, researchers had 
focused on uncovering mechanisms to block inflammation. 
It was believed that the cessation of inflammation and 
subsequent tissue repair was a passive process. In more recent 
years, many publications have uncovered this second phase 
is in fact orchestrated by a plethora of different mediators and 
immunological cells that contribute actively to this process 
(Sugimoto et al., 2016). Cellular-membrane derived counterparts 
have also been shown to be involved in processes that promote 
tissue resolution and repair.
It is well documented that immune cells are efficient 
modulators of other immune cells. Aside from direct cell 
contact, the use of messengers either released directly into 
solution or contained within EVs, deliver instructions to 
the recipient cell. The most prominent and established role 
of EVs is in triggering pro-inflammatory process however, 
it has been repeatedly demonstrated that EVs can have 
immunosuppressive and resolutive roles in various contexts. 
Admyre et al. revealed that during pregnancy, breast milk 
contains EVs positive for MHC classes I and II; CD63, CD81, 
and CD86. These MHC classes I and II positive EVs inhibited 
the production of anti-CD3-induced IL-2 and IFN-γ from 
allogeneic and autologous polymorphonuclear cells. These 
subsets of EVs also increased the numbers of Foxp3+CD4 
+CD25+ T regulatory cells (Treg) (Admyre et al., 2007). 
Reduced cytotoxicity of Natural Killer, CD8+, and γδ T cells 
was also demonstrated after incubation of these cells with 
placental exosomes bearing NKG2D ligands (Hedlund et al., 
2009). Furthermore, EVs from amniotic fluid can modulate 
the cytokine production by monocytic cells (Bretz et al., 
2013). This immunosuppressive role was also extensively 
associated with dendritic cells-derived EV. Dendritic cells-
derived EVs were able to enhance CD4+CD25+ Treg activity 
(Yang et al., 2011). Dendritic cell-derived EVs overexpressing 
IL-10, blocked cell proliferation in a mixed lymphocyte 
reaction in vitro and delayed the onset of collagen-induced 
arthritis as well as suppressed arthritis progression in mice 
(Kim et al., 2005). Furthermore, the same group demonstrated 
that myeloid cell-derived EVs (MHCII+CD11b+EV) obtained 
from the blood of mice immunised with keyhole limpet 
hemocyanin antigen, reduced hypersensitivity upon a second 
challenge with the same antigen, suggesting that they might 
have an anti-allergic effect (Kim et al., 2007).
Neutrophil-derived EVs released from activated neutrophils 
at the site of inflammation are shown to enhance antimicrobial 
activity via expression of opsonin CR1 receptor and of different 
antimicrobial proteins, such as MPO and human leukocyte 
elastase (Hess et al., 1998). These findings were further confirmed 
by Timar et al., where only EVs produced by stimulation of 
neutrophils with opsonised particles were capable of significantly 
reducing bacterial growth and their effect was independent of 
opsonisation and superoxide generation (Figure  3). Instead, 
these EVs seemed to form large aggregates with bacteria, a 
process dependent upon cytoskeletal reorganization, β2 integrin 
function, glucose metabolism and PI3-kinase activity of EVs. 
This effect was lost when neutrophils were stimulated with 
other pro-inflammatory stimuli (Lorincz et al., 2015). Equally, 
neutrophil-derived EVs were enriched in neutrophils granule 
proteins, many of which are known to be antibacterial (Timár 
et al., 2013).
The role of leukocyte-derived EVs in the resolution of 
vascular inflammation and cardiovascular diseases still lacks 
full investigation. This role has been previously reported by 
our group, both in the context of vascular inflammation and 
autoimmune diseases, such as rheumatoid arthritis. Dalli et al. 
reported significantly reduced neutrophil recruitment and 
adhesion to endothelial cell monolayers when neutrophils were 
pre-incubated with neutrophil-derived EVs. These vesicles 
contained the pro-resolving protein AnxA1 (Dalli et al., 2008). 
This self-limiting and anti-inflammatory mechanism has 
been reiterated in further studies, where neutrophil-derived 
EVs were shown to enhance the efferocytosis of apoptotic 
neutrophils and biosynthesis of specialised pro-resolving 
mediators (SPMs) in macrophages, including: PGE2, RvD1, 
MaR1, and PGF2α (Figure 3). Interestingly, neutrophil-derived 
EVs do not contain mature SPMs (Dalli and Serhan, 2012), but 
contain SPM precursors esterified in EV membranes (Norling 
et al., 2011). Headland et al., demonstrated therapeutic roles 
of neutrophil-derived EVs in providing protection from 
cartilage damage in experimental arthritis via AnxA1. Elevated 
neutrophil-derived EVs present in the synovial fluid of 
rheumatoid arthritis patients were similarly enriched in AnxA1. 
Disruption of EV generation using the Tmem16f-/- genetically 
modified mouse, resulted in impaired cartilage integrity during 
inflammatory arthritis (Headland et al., 2015). Recently, our 
group also demonstrated a direct role of neutrophil-derived 
EVs in counteracting the classical activation of macrophages, 
a role which was dependent upon PtdSer and AnxA1. These 
EVs also promoted the release of TGF-β (Rhys et al., 2018). 
Additionally, AnxA1+ neutrophil-derived EVs obtained from 
polymyalgia rheumatica patients (24 weeks post-steroid 
treatment) modulated neutrophil phenotype to suppress T-cell 
reactivity and proliferation (Nadkarni et al., 2019).
Furthermore, stimulation of human neutrophils, either in 
suspension or adherent to endothelial monolayers, led to the 
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production of EVs with different proteomes, that differentially 
modulated endothelial genes (Dalli et al., 2013). Neutrophil-
derived EVs have also been proposed to play a protective role in 
the prevention of vascular leakage during leukocyte extravasation, 
either by forming a physical barrier on the sub-endothelium or by 
inducing signaling events that regulate vascular barrier function 
(Lim et al., 2013). Interestingly, monocyte-derived EVs seem to be 
linked to tissue repair in bone regeneration. In 2013, Ekstrom et al., 
demonstrated that monocyte-derived Exos obtained from cells 
stimulated with LPS were able to induce osteogenic differentiation 
of mesenchymal stem cells (MSC), enhancing the expression 
of RUNX2 and BMP-2; genes important in bone regeneration 
(Figure  3) (Ekström et al., 2013). Moreover, Exos derived from 
donor immature dendritic cells prolonged cardiac allograft survival 
by inhibiting T-cell activation. In this study, researchers found that 
the combination of immature dendritic cells and rapamycin notably 
increased the percentage of CD4+CD25+ T cells and up-regulated 
Foxp3 expression in recipient splenic T cells, but did not confirm 
whether these CD4+CD25+ cells were Tregs (Li et al., 2012b).
A number of studies have underlined the physiological role 
of endothelial-derived EVs acting as intercellular messengers, 
promoting endothelial regeneration and vascular protection in 
vitro and in vivo. Vascular resolution often appears to be promoted 
through the use of miRNAs. For example, a study reported the ability 
of EC-derived EVs to suppress monocyte activation, due to their 
anti-inflammatory miRNA content. In particular, miR-10a was 
identified as a possible candidate, shown to repress inflammatory 
signaling by targeting several components of the NF-κB pathway, 
including IRAK4 (Njock et al., 2015). Exos secreted from EC which 
overexpressed hypoxia-inducible factor 1 (HIF1), can be taken up 
by transplanted cardiac progenitor cells (CPCs) at the infarcted 
area (in a mouse model of MI) and increase miR-126 and miR-210 
levels in CPCs (Ong et al., 2014). These mi-RNAs activated pro-
survival kinases and induced a glycolytic switch in recipient CPCs, 
increasing the tolerance of these cells to hypoxic stress. Inhibiting 
both of these miRNAs blocked the protective effects of the Exos 
(Ong et al., 2014). This study highlights EV-miRNA trafficking as a 
possible mechanism of molecular cross-talk to promote resolution, 
one that could be utilised therapeutically. Moreover, Jansen et al., 
demonstrated the systemic treatment of mice with EC-derived EVs 
(isolated from starved human coronary artery EC), after electric 
denudation of the endothelium, accelerated re-endothelialisation. 
FIGURE 3 | Extracellular vesicles promote tissue repair and regeneration. Schematic representation of the potential role of in vitro-generated extracellular vesicles 
(EVs) in tissue repair and resolution. Neutrophil EVs are able to promote cartilage protection and regeneration inducing pro-resolving mediators in macrophages 
and reducing the recruitment of cells to the endothelium. They also have antibacterial properties. Monocyte EVs are able to activate mesenchymal stem cells and 
enhance their osteogenic differentiation. Endothelial cell EVs promote angiogenesis and vascular repair, reducing activation of monocyte and smooth muscle cells. 
They are also able to increase glycolysis in cardiomyocytes and increase activation of endothelial cells and fibroblasts. Finally, stem cell EVs are shown to exert 
cardioprotective effects interacting with both leukocytes and cardiac cells.
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Whilst investigating the mechanism in vitro, they found that 
EC-derived EVs containing miR-126, promoted EC migration 
and proliferation through the active regulation of sprouty-related, 
EVH1 domain-containing protein 1 (SPRED1). This effect was 
abrogated both in vitro and in vivo when miR-126 was knocked 
down in EVs and when EVs were isolated from EC when glucose 
was reintroduced (Jansen et al., 2013). A similar effect of this 
specific miRNA delivered through EC-derived EVs was described 
also in VSMC (Jansen et  al., 2017). In this second study, they 
demonstrated that systemic treatment of mice with EC-derived 
EVs after vascular injury reduced neointima formation in vivo. In 
vitro, this mechanism was found to be miR-126 transfer dependent 
from EVs, acting to reduce VSMC proliferation by binding to target 
protein LRP6; a co-receptor of the Wnt signaling pathway. Analysis 
of miR-126 expression in circulating EVs of 176 patients with 
coronary artery disease, revealed a reduced percutaneous coronary 
intervention rate in patients with high miR-126 expression levels, 
supporting a central role for EV-incorporated miR-126 in vascular 
remodeling. The same group also showed in vitro and in vivo anti-
inflammatory actions of endothelial-derived EVs by promoting 
decreased expression of endothelial ICAM-1 through miRNA-
222 transfer (Jansen et al., 2015). Furthermore, EC-derived EVs 
also appear to promote endothelial cell survival. Endothelial 
cells can actively remove caspase-3 via incorporation into EVs, 
thereby reducing intracellular levels of the pro-apoptotic caspase-3 
(Hussein et al., 2005) (Figure 3). In line with this, endothelial and 
endothelial-regenerating cells were protected against apoptosis by 
AnxA1/PtdSer receptor-dependent EV uptake (Jansen et al., 2012). 
Similarly, human coronary artery EC exposed to EC-derived 
EVs, inhibited camptothecin-induced p38 activation. Moreover, 
endothelial-derived EVs containing endothelial protein C receptor 
and activated protein C were shown to promote cell survival by 
stimulation of cytoprotective effects (Pérez-Casal et al., 2009).
A recent publication has shown that EC have the ability to 
release cardioprotective Exos that may contribute to ischemic 
pre-conditioning. Cultured EC release EVs that were found 
to protect rat cardiomyocytes against subsequent exposure to 
hypoxia and reoxygenation (Davidson et al., 2018b). To address 
this mechanism of protection, the authors utilised an ERK1/2 
inhibitor, as they previously demonstrated cardioprotection by 
plasma EVs was dependent on ERK1/2 signaling and activation 
of the TLR4 receptor pathway by HSP70 on the vesicle surface. 
However the exact mechanism by which HUVEC EVs activate 
ERK1/2 in cardiomyocytes remains unknown since these vesicles 
did not appear to contain HSP70 (Vicencio et al., 2015).
Endothelial progenitor cell-derived EVs are ascribed the 
ability to regulate fibroblast differentiation to an endothelial cell 
phenotype. Human endothelial progenitor cell-derived EVs were 
also able to enhance the proliferation and angiogenesis of cardiac 
fibroblasts (CF) in vitro. Furthermore, CF stimulated with these 
Exos displayed higher expression of the EC-specific markers, such 
as CD31 and VEGF2, whilst reducing the expression of proteins 
involved in fibrosis; alpha-smooth muscle actin, vimentin, collagen 
I, TFG-β, and TNF-α. In addition, CF stimulated with endothelial 
progenitor cell-derived EVs, resulted in reduced expression of 
astrocytic-high mobility group box-1. Despite these findings 
suggesting a major role of EC-derived EVs in vascular regeneration, 
many contradictory reports suggest they play a role in the 
promotion of vascular inflammation. These conflicting accounts are 
most likely due to EV protein and miR composition (Huber et al., 
2002; Morel et al., 2008; Halkein et al., 2013; Yamamoto et al., 2015). 
Hosseinkhani et al., presented a good example of this dichotomous 
action. In their work, immunomodulatory content of EVs derived 
from unstimulated ECs and TNF-α induced ECs differently affected 
the inflammatory status of recipient THP-1 monocytic cells and 
HUVEC. ELISA assays revealed that TNF-α induced EVs contain 
a pro-inflammatory profile and chemotactic mediators, including 
ICAM-1, CCL-2, IL-6, IL-8, CXCL-10, CCL-5 and TNF-α compared 
to EVs from unstimulated cells. Furthermore, TNF-α induced EVs 
were able to selectively transfer functional inflammatory mediators 
that increased IL-6, IL-8 and ICAM-1 levels in recipient HUVEC 
and promoted the adhesion and migration of THP-1 cells. Taken 
together, these findings highlight EC-derived EVs can become 
enriched in a cocktail of inflammatory markers, chemokines and 
cytokines, able to establish a targeted cross-talk between EC and 
monocytes (Hosseinkhani et al., 2018).
In recent decades, multipotent MSC-derived EVs are 
widely reported as promoters of tissue repair in cardiac tissue 
and pathologies associated with vascular inflammation. For 
example, rat bone marrow MSC-derived Exos increased neurite 
remodeling, neurogenesis and angiogenesis in the ischemic 
boundary zone in an induced stroke model (Xin et al., 2013). 
These tissue repair effects were also seen in a rat model of 
traumatic brain injury, alongside reduced neurovascular 
inflammation (Zhang et  al., 2017). Furthermore, in a mouse 
model of stroke, treatment with MSC-derived EVs presented 
with similar outcomes to MSC transplantation; moderating post-
ischemia peripheral blood lymphopenia and skewing towards 
brain remodeling (Doeppner et al., 2015). Stem cell-derived EVs 
have also been described to have an immunosuppressive role in 
other vascular inflammatory syndromes. As a relevant example, 
Embryonic Stem Cells (ESC)-derived EVs were incubated with 
monocytes with a resultant increase in the release of the anti-
inflammatory cytokine IL-10 and decreased production of pro-
inflammatory cytokines IL-1β and IL-12p40 (Figure 3). It was 
also shown that co-incubation of MSC-derived EVs with THP-1 
cells induced the differentiation of CD4+ CD25+ FoxP3+ Tregs 
(Zhang et al., 2014). Moreover, these EVs had an overall reducing 
effect on the severity of inflammation in a model of ischemia-
induced myocardium tissue damage, contributing considerably 
to the protection of heart function. This was demonstrated 
with both local effects; lower neutrophil and macrophage 
infiltration into heart tissue, as well as systemic reduction in 
white blood cell counts (Arslan et al., 2013). Interestingly, the 
immunosuppressive action of these EVs could be modulated 
by preconditioning their parent cells. For example, when EVs 
were isolated from MSC stimulated with LPS, their progeny 
EVs were more effective at driving M2 polarisation of THP-1 
cells and promoting closure of diabetic cutaneous wounds (Ti 
et al., 2015). Stem cell-derived EVs play a key role in reducing 
the extent of injury during myocardial ischemia reperfusion and 
in MI. In 2010 Lai et al., revealed purified Exos secreted by MSC 
could reduce myocardial ischemia/reperfusion injury using 
mouse models (Lai et al., 2010).
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Various experimental studies have confirmed that engineered 
CD34+ stromal cells are also able to release Exos containing 
proangiogenic factors, conveyed to infarcted mouse myocardium 
decreased infarct size and improved long-term regeneration 
(MacKie et al., 2012; Marrachelli et al., 2013). Arslan et al., 
demonstrated that treatment with MSC-derived EVs in the 
post-MI period actually improved myocardial viability and 
decreased adverse ventricular remodeling by reducing oxidative 
stress and activating the PI3K/Akt pathway (Arslan et al., 2013). 
Another type of stem cell acquiring growing interest for their 
potential roles in cardiac tissue repair, are the cardiosphere-
derived cells (CDCs). These cells show multi-lineage 
differentiation and are described in various preclinical models 
to improve cardiac function after delivery CDC-derived EVs to 
ischemic myocardium (De Couto et al., 2015; Tseliou et al., 2015). 
Curiously, the strong reduction in infarct size facilitated by CDC-
derived EVs has correlated with EV-YF1. This RNA belongs to a 
family of small noncoding RNA called Y RNA which are active 
components of the Ro60 ribonucleoprotein particle involved in 
DNA replication. Interestingly, the transfer of EV-YF1 by EV 
from CDCs to macrophages resulted in an increased expression 
of the immunosuppressive cytokine IL-10 (Cambier et al., 2017). 
Although there is some mechanistic understanding, how EVs 
promote cardioprotection is yet to be fully revealed. It appears to 
be the result of a direct interaction with cells in the heart, rather 
than blood components. Numerous studies have underlined the 
regeneration of post-infarct myocardium could be mediated by 
miRNA and that this could be enhanced by EV delivery from both 
cardiac and noncardiac SC. Among the most studied are MSC-
derived EVs containing miR-21 (Luther et al., 2018; Mayourian 
et al., 2018) and its different isoforms, which appear to be good 
candidates for cardiac tissue repair. MSC-derived EVs were very 
recently shown to exhibit cardioprotection by increasing the level 
of miR-21a-5p in recipient cardiac cells, thereby downregulating 
expression of the pro-apoptotic gene products PDCD4, PTEN, 
Peli1, and FasL in the myocardium (Luther et al., 2018). Another 
study highlighted that induced pluripotent SC-derived EV 
miR-21 and HIF-1α-regulated exosomal miR-210, can induce 
cytoprotective signals to cardiomyocytes in in vitro setting of 
myocardial ischemia/reperfusion (Wang et al., 2015b). In line 
with this, Feng Y et al., revealed that the upregulation of miR-
22 in MSC exposed to ischemic preconditioning, led to the 
transfer of this miRNA into EVs. When these EVs were injected 
into infarcted mouse hearts, they improved the repair of tissue 
damage resulting from MI and the mechanism for this involved 
the downregulation of Mecp2 (methyl CpG binding protein 2) 
(Feng et al., 2014). Interestingly, the same profibrotic protein 
MEcp2 was found to be modulated by miR-132. This miRNA 
was first described in perivascular pericytes and was shown to be 
transferred in EC via an EV mediated mechanism. Furthermore, 
cardiac progenitor cell exosomal miR-451 was found to improve 
clinical outcomes when mouse hearts were injected with EVs 
after the induction of ischemia (Chen et al., 2013). Finally, EVs 
containing miR-223, the most highly expressed miRNA in bone 
marrow-derived MSCs, downregulated Sema3A and Stat3 and 
reduced levels of pro-inflammatory cytokines in a sepsis-triggered 
cardiac injury model. The reduction of cardiomyocyte death 
during sepsis and enhanced cardiac function were attributed to 
the action of miR-223, which was able to downregulate various 
inflammation related genes such as Mef2C, PKnox1, CXCL2, 
CCL3, IL-6, NLRP3, TANK, DR6, and IRF4 (Wang et al., 2015) 
(Figure 3). EVs released from other cell types, for example, 
injured cardiomyocytes have also been reported to contain some 
cardiac-specific miRNAs, particularly miR-1, miR-133a, and 
miR-208 and activate cardiac muscle cells and resident cardiac 
progenitor cells to initiate cardiac tissue repair (Chistiakov et al., 
2012). Moreover, plasma exosomes isolated from human or rat 
blood by differential ultracentrifugation exhibit a cardioprotective 
effect, decreasing infarct size when administered intravenously 
to rats or primary cardiomyocytes. The same group established 
that the presence of HSP70 on the surface of EVs was able to 
activate the ERK1/2 pathway through stimulation of TLR4, and 
inhibition of these mechanisms led to reduced cardioprotection 
(Vicencio et al., 2015). This cardioprotective effect however, was 
completely lost when these EVs were isolated from the blood of 
rats or humans with type II diabetes, suggesting plasma EVs may 
continually exhibit, mild stimulatory effects on cardioprotective 
pathways in the heart during physiological conditions and not 
during vascular pathologies (Davidson et al., 2018a).
THERAPEUTIC POTENTIAL OF EVS
The ubiquitous nature and endogenous properties of EVs poses 
them as novel therapeutic strategies in the treatment of diseases. EVs 
have the potential to generate efficacious effects in pathology with 
the added benefit of circumventing drug side-effects. For example, 
MSC-derived EVs were shown to enhance repair in damaged 
cardiac tissue (El Andaloussi et al., 2013), EVs were able to reduce 
infarct size and improve left ventricle ejection fraction following 
ischemia (Ciullo et al., 2019) and interestingly, EVs derived from 
DCs have been used as part of cancer immunotherapeutics (Zitvogel 
et al., 1998). It is not only the biological content of EVs that can be 
harnessed, but they can also act as scaffolds, providing the vehicle 
through which active compounds can be administered, masked by 
the membrane encapsulation of “self.” Human neutrophil-derived 
EVs, enriched with lipid mediators such as aspirin-triggered 
resolvin D1 or lipoxin A4 exhibited therapeutic properties including 
reduced neutrophil cell influx during in vivo peritonitis models and 
improved resolution of inflammation; demonstrated by accelerated 
keratinocyte healing (Norling et al., 2011).
CONCLUDING REMARKS
Researchers have gleamed a wealth of information from studying 
EVs in health and disease, identifying their use as biomarkers of 
inflammatory diseases and exploring their repertoire of functions. 
We have highlighted here the yin and yang of EVs in the context 
of cardiovascular disease; promoting vascular inflammation 
yet also initiating resolution and repair mechanisms. We have 
iterated how the composition of EVs are dependent upon the 
parent cell status and active transfer of specific miRNA, receptors, 
enzymes, lipids, and proteins that yields functional vectors that 
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influence the phenotype of recipient cells. Together, the breadth 
of information we have discussed in this article indicates the 
powerful nature of these tiny organelles and their utility to be 
manipulated for therapeutic purposes.
AUTHOR CONTRIBUTIONS
SO and SA-W contributed equally to writing this manuscript. All 
authors planned, edited, and reviewed the article prior to submission.
FUNDING
SO is supported by EVOluTION that has received funding 
from the European Union’s Horizon 2020 research and 
innovation program under the Marie Sklodowska-Curie 
grant agreement No. 675111. SA-W and LN are supported 
by a Versus Arthritis PhD Studentship and Senior Research 
Fellowship (grants 21941 and 22235 respectively). LVN is 
also supported by Barts Charity (Project grant MGU0443). 
This work has been facilitated by the National Institute for 
Health Research Biomedical Research Centre at Barts Hospital 
NHS Trust.
ACKNOwLEDGMENTS
We would like to thank Miss Millie Davan Wetton for 
proofreading the manuscript. The authors acknowledge the 
support of the Biorender software for generating the figures.
REFERENCES
Abad Hussein M N, Nieuwland R., Hau, C. M., Evers, L. M., Meesters, E. W., and 
Sturk, A. (2005). Cell-derived microparticles contain caspase 3 in vitro and in 
vivo. J. Thromb. Haemost. 3, 888–896. doi: 10.1111/j.1538-7836.2005.01240.x
Admyre, C., Johansson, S. M., Qazi, K. R., Filén, J.-J., Lahesmaa, R., Norman, M., 
et al. (2007). Exosomes with immune modulatory features are present in human 
breast milk. J. Immunol. 179, 1969–1978. doi: 10.4049/jimmunol.179.3.1969
Aharon, A., Tamari, T., and Brenner, B. (2008). Monocyte-derived microparticles 
and exosomes induce procoagulant and apoptotic effects on endothelial cells. 
Thromb. Haemost. 100, 878–885. doi: 10.1160/TH07-11-0691
Arslan, F., Lai, R. C., Smeets, M. B., Akeroyd, L., Choo, A., Aguor, E. N. E., et al. 
(2013). Mesenchymal stem cell-derived exosomes increase ATP levels, decrease 
oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability 
and prevent adverse remodeling after myocardial ischemia/reperfusion injury. 
Stem Cell Res. 10, 301–312. doi: 10.1016/j.scr.2013.01.002
Badimon, L., Padró, T., and Vilahur, G. (2012). Atherosclerosis, platelets and 
thrombosis in acute ischaemic heart disease. Eur. Hear. J. Acute Cardiovasc. 
Care 1, 60–74. doi: 10.1177/2048872612441582
Baietti, M. F., Zhang, Z., Mortier, E., Melchior, A., Degeest, G., Geeraerts, A., et al. 
(2012). Syndecan–syntenin–ALIX regulates the biogenesis of exosomes. Nat. 
Cell Biol. 14, 677–685. doi: 10.1038/ncb2502
Bala, S., Marcos, M., Kodys, K., Csak, T., Catalano, D., Mandrekar, P., et al. (2011). 
Up-regulation of MicroRNA-155 in macrophages contributes to increased 
tumor necrosis factor α (TNFα) production via increased mRNA half-life 
in alcoholic liver disease. J. Biol. Chem. 286, 1436–1444. doi: 10.1074/jbc.
M110.145870
Balaj, L., Lessard, R., Dai, L., Cho, Y.-J., Pomeroy, S. L., Breakefield, X. O., et al. 
(2011). Tumour microvesicles contain retrotransposon elements and amplified 
oncogene sequences. Nat. Commun. 2, 180. doi: 10.1038/ncomms1180
Banks, W. A., Gray, A. M., Erickson, M. A., Salameh, T. S., Damodarasamy, M., 
Sheibani, N., et al. (2015). Lipopolysaccharide-induced blood-brain barrier 
disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and 
elements of the neurovascular unit. J. Neuroinflammation 12, 223. doi: 10.1186/
s12974-015-0434-1
Bao, H., Yao, Q.-P., Huang, K., Chen, X.-H., Han, Y., Jiang, Z.-L., et al. (2017). 
Platelet-derived miR-142-3p induces apoptosis of endothelial cells in 
hypertension. Cell. Mol. Biol. 63, 3. doi: 10.14715/cmb/2017.63.4.1
Bao, H., Chen, Y.-X., Huang, K., Zhuang, F., Bao, M., Han, Y., et al. (2018). 
Platelet-derived microparticles promote endothelial cell proliferation 
in hypertension via miR-142-3p. FASEB J. 32, 3912–3923. doi: 10.1096/
fj.201701073R
Bardelli, C., Amoruso, A., Federici Canova, D., Fresu, L., Balbo, P., Neri, T., et al. 
(2012). Autocrine activation of human monocyte/macrophages by monocyte-
derived microparticles and modulation by PPARγ ligands. Br. J. Pharmacol. 
165, 716–728. doi: 10.1111/j.1476-5381.2011.01593.x
Barry, O. P., Praticò, D., Lawson, J. A., and FitzGerald, G. A. (1997). Transcellular 
activation of platelets and endothelial cells by bioactive lipids in platelet 
microparticles. J. Clin. Invest. 99, 2118–2127. doi: 10.1172/JCI119385
Barry, O. P., Kazanietz, M. G., Praticò, D., and FitzGerald, G. A. (1999). 
Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-
dependent prostaglandin formation via a protein kinase C/Mitogen-activated 
protein kinase-dependent pathway. J. Biol. Chem. 274, 7545–7556. doi: 10.1074/
jbc.274.11.7545
Barwari, T., Joshi, A., and Mayr, M. (2016). MicroRNAs in cardiovascular disease. 
J. Am. Coll. Cardiol. 68, 2577–2584. doi: 10.1016/j.jacc.2016.09.945
Beaudoin, A. R., and Grondin, G. (1991). Shedding of vesicular material from the 
cell surface of eukaryotic cells: different cellular phenomena. Biochim. Biophys. 
Acta-Rev. Biomembr. 1071, 203–219. doi: 10.1016/0304-4157(91)90014-N
Bonifacino, J. S., and Glick, B. S. (2004). The mechanisms of vesicle budding and 
fusion. Cell 116, 153–166. doi: 10.1016/S0092-8674(03)01079-1
Boudreau, L. H., Duchez, A.-C., Cloutier, N., Soulet, D., Martin, N., Bollinger, J., 
et al. (2014). Platelets release mitochondria serving as substrate for bactericidal 
group IIA-secreted phospholipase A2 to promote inflammation. Blood 124, 
2173–2183. doi: 10.1182/blood-2014-05-573543
Bretz, N. P., Ridinger, J., Rupp, A.-K., Rimbach, K., Keller, S., Rupp, C., et al. 
(2013). Body fluid exosomes promote secretion of inflammatory cytokines 
in monocytic cells via toll-like receptor signaling. J. Biol. Chem. 288, 36691–
36702. doi: 10.1074/jbc.M113.512806
Brill, A., Dashevsky, O., Rivo, J., Gozal, Y., and Varon, D. (2005). Platelet-derived 
microparticles induce angiogenesis and stimulate post-ischemic revascularization. 
Cardiovasc. Res. 67, 30–38. doi: 10.1016/j.cardiores.2005.04.007
Brodsky, S. V., Malinowski, K., Golightly, M., Jesty, J., and Goligorsky, M. S. 
(2002). Plasminogen activator inhibitor-1 promotes formation of endothelial 
microparticles with procoagulant potential. Circulation 106, 2372–2378. doi: 
10.1161/01.CIR.0000033972.90653.AF
Brogan, P. A., Shah, V., Brachet, C., Harnden, A., Mant, D., Klein, N., et al. (2004). 
Endothelial and platelet microparticles in vasculitis of the young. Arthritis 
Rheumatol. 50, 927–936. doi: 10.1002/art.20199
Brown, G. T., and McIntyre, T. M. (2011). Lipopolysaccharide signaling without 
a nucleus: kinase cascades stimulate platelet shedding of proinflammatory 
IL-1β–Rich Microparticles. J. Immunol. 186, 5489–5496. doi: 10.4049/
jimmunol.1001623
Buschow, S. I., Nolte-‘t Hoen, E. N. M., van Niel, G., Pols, M. S., ten Broeke, T., 
Lauwen, M., et al. (2009). MHC II in dendritic cells is targeted to lysosomes or 
T cell-induced exosomes via distinct multivesicular body pathways. Traffic 10, 
1528–1542. doi: 10.1111/j.1600-0854.2009.00963.x
Bustos, M., Saadi, S., and Platt, J. L. (2001). Platelet-mediated activation of 
endothelial cells: implications for the pathogenesis of transplant rejection1. 
Transplantation 72, 509–515. doi: 10.1097/00007890-200108150-00025
Cambier, L., Couto, G., Ibrahim, A., Echavez, A. K., Valle, J., Liu, W., et al. 
(2017). Y RNA fragment in extracellular vesicles confers cardioprotection via 
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1479
The Contrasting Role of Extracellular VesiclesOggero et al.
17
modulation of IL -10 expression and secretion. EMBO Mol. Med. 9, 337–352. 
doi: 10.15252/emmm.201606924
Chairoungdua, A., Smith, D. L., Pochard, P., Hull, M., and Caplan, M. J. (2010). 
Exosome release of β-catenin: A novel mechanism that antagonizes Wnt 
signaling. J. Cell Biol. 190, 1079–1091. doi: 10.1083/jcb.201002049
Charrin, S., Jouannet, S., Boucheix, C., and Rubinstein, E. (2014). Tetraspanins at 
a glance. J. Cell Sci. 127, 3641–3648. doi: 10.1242/jcs.154906
Chen, Q., Wang, H., Liu, Y., Song, Y., Lai, L., Han, Q., et al. (2012). Inducible 
microrna-223 down-regulation promotes tlr-triggered il-6 and il-1β production 
in macrophages by targeting stAT3. PloS One 7, e42971. doi: 10.1371/journal.
pone.0042971
Chen, L., Wang, Y., Pan, Y., Zhang, L., Shen, C., Qin, G., et al. (2013). Cardiac 
progenitor-derived exosomes protect ischemic myocardium from acute 
ischemia/reperfusion injury. Biochem. Biophys. Res. Commun. 431, 566–571. 
doi: 10.1016/j.bbrc.2013.01.015
Chironi, G., Simon, A., Hugel, B., Pino, M. D., Gariepy, J., Freyssinet, J. M., et al. 
(2006). Circulating leukocyte-derived microparticles predict subclinical 
atherosclerosis burden in asymptomatic subjects. Arterioscler. Thromb. Vasc. 
Biol. 26, 2775–2780. doi: 10.1161/01.ATV.0000249639.36915.04
Chistiakov, D. A., Sobenin, I. A., and Orekhov, A. N. (2012). Strategies to deliver 
microRNAs as potential therapeutics in the treatment of cardiovascular 
pathology. Drug Deliv. 19, 392–405. doi: 10.3109/10717544.2012.738436
Chiva-Blanch, G., Suades, R., Crespo, J., Vilahur, G., Arderiu, G., Padró, T., et al. 
(2016). CD3 + /CD45 + and SMA-α + circulating microparticles are increased in 
individuals at high cardiovascular risk who will develop a major cardiovascular 
event. Int. J. Cardiol. 208, 147–149. doi: 10.1016/j.ijcard.2016.01.211
Christersson, C., Thulin, Å., and Siegbahn, A. (2017). Microparticles during long-
term follow-up after acute myocardial infarction: association to atherosclerotic 
burden and risk of cardiovascular events. Thromb. Haemost. 117, 1571–1581. 
doi: 10.1160/TH16-11-0837
Cines, D. B., and McMillan, R. (2005). Management of adult idiopathic 
thrombocytopenic purpura. Annu. Rev. Med. 56, 425–442. doi: 10.1146/
annurev.med.56.082103.104644
Ciullo, A., Biemmi, V., Milano, G., Bolis, S., Cervio, E., Fertig, E. T., et al. (2019). 
Exosomal expression of CXCR4 targets cardioprotective vesicles to myocardial 
infarction and improves outcome after systemic administration. Int. J. Mol. Sci. 
20, 468. doi: 10.3390/ijms20030468
Clarke, L. A., Hong, Y., Eleftheriou, D., Shah, V., Arrigoni, F., Klein, N. J., et al. 
(2010). Endothelial injury and repair in systemic vasculitis of the young. 
Arthritis Rheumatol. 62, 1770–1780. doi: 10.1002/art.27418
Coleman, M. L., Sahai, E. A., Yeo, M., Bosch, M., Dewar, A., and Olson, M. F. 
(2001). Membrane blebbing during apoptosis results from caspase-mediated 
activation of ROCK I. Nat. Cell Biol. 3, 339–345. doi: 10.1038/35070009
Collino, F., Deregibus, M. C., Bruno, S., Sterpone, L., Aghemo, G., Viltono, L., 
et al. (2010). Microvesicles derived from adult human bone marrow and tissue 
specific mesenchymal stem cells shuttle selected pattern of miRNAs. PloS One 
5, e11803. doi: 10.1371/journal.pone.0011803
Combes, V., Simon, A. C., Grau, G. E., Arnoux, D., Camoin, L., Sabatier, F., 
et  al. (1999). In vitro generation of endothelial microparticles and possible 
prothrombotic activity in patients with lupus anticoagulant. J. Clin. Invest. 104, 
93–102. doi: 10.1172/JCI4985
Connor, D. E., Exner, T., Ma, D. D. F., and Joseph, J. E. (2009). Detection of 
the procoagulant activity of microparticle-associated phosphatidylserine 
using XACT. Blood Coagul. Fibrinolysis 20, 558–564. doi: 10.1097/
MBC.0b013e32832ee915
Connor, D. E., Exner, T., Ma, D. D. F., and Joseph, J. E. (2010). The majority 
of circulating platelet-derived microparticles fail to bind annexin V, lack 
phospholipid-dependent procoagulant activity and demonstrate greater 
expression of glycoprotein Ib. Thromb. Haemost. 103, 1044–1052. doi: 10.1160/
TH09-09-0644
Conti, L., Hiscott, J., Papacchini, M., Roulston, A., Wainberg, M. A., Belardelli, F., 
et al. (1997). Induction of relA(p65) and I kappa B alpha subunit expression 
during differentiation of human peripheral blood monocytes to macrophages. 
Cell Growth Differ. 8, 435–442.
Cordazzo, C., Neri, T., Petrini, S., Lombardi, S., Balìa, C., Cianchetti, S., et al. 
(2013). Angiotensin II induces the generation of procoagulant microparticles 
by human mononuclear cells via an angiotensin type 2 receptor-mediated 
pathway. Thromb. Res. 131, e168–e174. doi: 10.1016/j.thromres.2013.01.019
Dalli, J., and Serhan, C. N. (2012). Specific lipid mediator signatures of human 
phagocytes: Microparticles stimulate macrophage efferocytosis and pro-
resolving mediators. Blood 120, e60–e72. doi: 10.1182/blood-2012-04-423525
Dalli, J., Norling, L. V., Renshaw, D., Cooper, D., Leung, K. Y., and Perretti, M. (2008). 
Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived 
microparticles. Blood 112, 2512–2519. doi: 10.1182/blood-2008-02-140533
Dalli, J., Montero-Melendez, T., Norling, L. V., Yin, X., Hinds, C., Haskard, D., et al. 
(2013). Heterogeneity in neutrophil microparticles reveals distinct proteome 
and functional properties. Mol. Cell. Proteomics 12, 2205–2219. doi: 10.1074/
mcp.M113.028589
Dalvi, P., Sun, B., Tang, N., and Pulliam, L. (2017). Immune activated monocyte 
exosomes alter microRNAs in brain endothelial cells and initiate an 
inflammatory response through the TLR4/MyD88 pathway. Sci. Rep. 7, 9954. 
doi: 10.1038/s41598-017-10449-0
Daniel, L., Fakhouri, F., Joly, D., Mouthon, L., Nusbaum, P., Grunfeld, J.-P., et al. 
(2006). Increase of circulating neutrophil and platelet microparticles during 
acute vasculitis and hemodialysis. Kidney Int. 69, 1416–1423. doi: 10.1038/
sj.ki.5000306
Dasgupta, S. K., Abdel-Monem, H., Niravath, P., Le, A., Bellera, R. V., Langlois, K., 
et al. (2009). Lactadherin and clearance of platelet-derived microvesicles. Blood 
113, 1332–1339. doi: 10.1182/blood-2008-07-167148
Davidson, S. M., Riquelme, J. A., Takov, K., Vicencio, J. M., Boi-Doku, C., Khoo, V., 
et al. (2018a). Cardioprotection mediated by exosomes is impaired in the setting 
of type II diabetes but can be rescued by the use of non-diabetic exosomes in 
vitro. J. Cell. Mol. Med. 22, 141–151. doi: 10.1111/jcmm.13302
Davidson, S. M., Riquelme, J. A., Zheng, Y., Vicencio, J. M., Lavandero, S., and 
Yellon, D. M. (2018b). Endothelial cells release cardioprotective exosomes that 
may contribute to ischaemic preconditioning. Sci. Rep. 8, 15885. doi: 10.1038/
s41598-018-34357-z
De Couto, G., Liu, W., Tseliou, E., Sun, B., Makkar, N., Kanazawa, H., et al. 
(2015). Macrophages mediate cardioprotective cellular postconditioning in 
acute myocardial infarction. J. Clin. Invest. 125, 3147–3162. doi: 10.1172/
JCI81321
Deatherage, B. L., and Cookson, B. T. (2012). Membrane vesicle release in bacteria, 
eukaryotes, and archaea: a conserved yet underappreciated aspect of microbial 
life. Infect. Immun. 80, 1948–1957. doi: 10.1128/IAI.06014-11
Diehl, K. H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., 
et al. (2001). A good practice guide to the administration of substances and 
removal of blood, including routes and volumes. J. Appl. Toxicol. 21, 15–23. 
doi: 10.1002/jat.727
Diehl, P., Fricke, A., Sander, L., Stamm, J., Bassler, N., Htun, N., et al. (2012). 
Microparticles: Major transport vehicles for distinct microRNAs in circulation. 
Cardiovasc. Res. 93, 633–644. doi: 10.1093/cvr/cvs007
Dignat-George, F., and Boulanger, C. M. (2011). The many faces of endothelial 
microparticles. Arterioscler. Thromb. Vasc. Biol. 31, 27–33. doi: 10.1161/
ATVBAHA.110.218123
Doeppner, T. R., Herz, J., Görgens, A., Schlechter, J., Ludwig, A.-K., Radtke, S., 
et al. (2015). Extracellular vesicles improve post-stroke neuroregeneration and 
prevent postischemic immunosuppression. Stem Cells Transl. Med. 4, 1131–
1143. doi: 10.5966/sctm.2015-0078
Duchez, A.-C., Boudreau, L. H., Naika, G. S., Bollinger, J., Belleannée, C., Cloutier, 
N., et al. (2015). Platelet microparticles are internalized in neutrophils via the 
concerted activity of 12-lipoxygenase and secreted phospholipase A 2 -IIA. 
Proc. Natl. Acad. Sci. 112, E3564–E3573. doi: 10.1073/pnas.1507905112
Ekström, K., Omar, O., Granéli, C., Wang, X., Vazirisani, F., and Thomsen, P. (2013). 
Monocyte exosomes stimulate the osteogenic gene expression of mesenchymal 
stem cells. PloS ONE 8, e75227. doi: 10.1371/journal.pone.0075227
El Andaloussi, S., Mäger, I., Breakefield, X. O., and Wood, M. J. A. (2013). 
Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat. 
Rev. Drug Discovery 12, 347–357. doi: 10.1038/nrd3978
Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicol. Pathol. 
35, 495–516. doi: 10.1080/01926230701320337
Erdbruegger, U., Grossheim, M., Hertel, B., Wyss, K., Kirsch, T., Woywodt,  A., 
et al. (2008). Diagnostic role of endothelial microparticles in vasculitis. 
Rheumatology 47, 1820–1825. doi: 10.1093/rheumatology/ken373
Essayagh, S., Xuereb, J.-M., Terrisse, A.-D., Tellier-Cirioni, L., Pipy, B., and 
Sié, P. (2007). Microparticles from apoptotic monocytes induce transient 
platelet recruitment and tissue factor expression by cultured human vascular 
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1479
The Contrasting Role of Extracellular VesiclesOggero et al.
18
endothelial cells via a redox-sensitive mechanism. Thromb. Haemost. 98, 831–
837. doi: 10.1160/TH07-02-0082
Faure, V., Dou, L., Sabatier, F., Cerini, C., Sampol, J., Berland, Y., et al. 
(2006). Elevation of circulating endothelial microparticles in patients 
with chronic renal failure. J. Thromb. Haemost. 4, 566–573. doi: 
10.1111/j.1538-7836.2005.01780.x
Feng, B., Chen, Y., Luo, Y., Chen, M., Li, X., and Ni, Y. (2010). Circulating level of 
microparticles and their correlation with arterial elasticity and endothelium-
dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 
208, 264–269. doi: 10.1016/j.atherosclerosis.2009.06.037
Feng, Y., Huang, W., Wani, M., Yu, X., and Ashraf, M. (2014). Ischemic 
preconditioning potentiates the protective effect of stem cells through secretion 
of exosomes by targeting Mecp2 via miR-22. PloS One 9, e88685. doi: 10.1371/
journal.pone.0088685
Flaumenhaft, R., Mairuhu, A., and Italiano, J. (2010). Platelet- and Megakaryocyte-
Derived Microparticles. Semin. Thromb. Hemost. 36, 881–887. doi: 
10.1055/s-0030-1267042
Fonseca, P., Vardaki, I., Occhionero, A., and Panaretakis, T. (2016). “Metabolic and 
signaling functions of cancer cell-derived extracellular vesicles,” in. Int. Rev. 
Cell Mol. Biol. 326, 175–199. doi: 10.1016/bs.ircmb.2016.04.004
Forlow, S. B., McEver, R. P., and Nollert, M. U. (2000). Leukocyte-leukocyte 
interactions mediated by platelet microparticles under flow. Blood 95, 1317–
1323. doi: 10.1182/blood.V95.4.1317.004k30_1317_1323
Furlan, J. C., Fang, J., and Silver, F. L. (2016). Outcomes after acute ischemic stroke 
in patients with thrombocytopenia or thrombocytosis. J. Neurol. Sci. 362, 198–
203. doi: 10.1016/j.jns.2016.01.044
Gaetani, E., Del Zompo, F., Marcantoni, M., Gatto, I., Giarretta, I., Porfidia, A., 
et al. (2018). Microparticles produced by activated platelets carry a potent and 
functionally active angiogenic signal in subjects with Crohn’s disease. Int. J. 
Mol. Sci. 19, 2921. doi: 10.3390/ijms19102921
Gasser, O., and Schifferli, J. A. (2004). Activated polymorphonuclear neutrophils 
disseminate anti-inflammatory microparticles by ectocytosis. Blood 104, 2543–
2548. doi: 10.1182/blood-2004-01-0361
Gasser, O., Hess, C., Miot, S., Deon, C., Sanchez, J. C., and Schifferli, J. ür. A. 
(2003). Characterisation and properties of ectosomes released by human 
polymorphonuclear neutrophils. Exp. Cell Res. 285, 243–257. doi: 10.1016/
S0014-4827(03)00055-7
Gidlöf, O., van der Brug, M., öhman, J., Gilje, P., Olde, B., Wahlestedt, C., et al. 
(2013). Platelets activated during myocardial infarction release functional 
miRNA, which can be taken up by endothelial cells and regulate ICAM1 
expression. Blood 121, 3908–3917. doi: 10.1182/blood-2012-10-461798
Gkaliagkousi, E., Passacquale, G., Douma, S., Zamboulis, C., and Ferro, A. (2010). 
Platelet activation in essential hypertension: implications for antiplatelet 
treatment. Am. J. Hypertens. 23, 229–236. doi: 10.1038/ajh.2009.247
Goñi, F. M., and Alonso, A. (2009). Effects of ceramide and other simple 
sphingolipids on membrane lateral structure. Biochim. Biophys. Acta - 
Biomembr. 1788, 169–177. doi: 10.1016/j.bbamem.2008.09.002
Goichot, B., Grunebaum, L., Desprez, D., Vinzio, S., Meyer, L., Schlienger, J. L., 
et  al. (2006). Circulating procoagulant microparticles in obesity. Diabetes 
Metab. 32, 82–85. doi: 10.1016/S1262-3636(07)70251-3
Gomez, I., Ward, B., Evans, P., Hellewell, P., and Ridger, V. (2015). YIA2 Neutrophil 
Microvesicles Influence Atherogenesis and Contain Mirna. Heart 101, A122–
A123. doi: 10.1136/heartjnl-2015-308066.225
Gomez, I., Ward, B., Souilhol, C., Recarti, C., Ariaans, M., Johnston, J., et al. 
(2018). Neutrophil microvesicles drive atherosclerosis by delivering miR-155 
to atheroprone endothelium. bioRxiv 319392. doi: 10.1101/319392
Guescini, M., Genedani, S., Stocchi, V., and Agnati, L. F. (2010). Astrocytes and 
Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. 117, 
1–4. doi: 10.1007/s00702-009-0288-8
Halkein, J., Tabruyn, S. P., Ricke-Hoch, M., Haghikia, A., Nguyen, N. Q. N., Scherr, 
M., et al. (2013). MicroRNA-146a is a therapeutic target and biomarker for 
peripartum cardiomyopathy. J. Clin. Invest. 123, 2143–2154. doi: 10.1172/
JCI64365
Happonen, K. E., Tran, S., Mörgelin, M., Prince, R., Calzavarini, S., Angelillo-
Scherrer, A., et al. (2016). The Gas6-Axl protein interaction mediates 
endothelial uptake of platelet microparticles. J. Biol. Chem. 291, 10586–10601. 
doi: 10.1074/jbc.M115.699058
Hargett, L. A., and Bauer, N. N. (2013). On the origin of microparticles: from 
“platelet dust” to mediators of intercellular communication. Pulm. Circ. 3, 
329–340. doi: 10.4103/2045-8932.114760
Hawrylowicz, C. M. (1991). Platelet-derived interleukin 1 induces human 
endothelial adhesion molecule expression and cytokine production. J. Exp. 
Med. 174, 785–790. doi: 10.1084/jem.174.4.785
Hay, J. C., and Scheller, R. H. (1997). SNARES and NSF in targeted membrane 
fusion. Curr. Opin. Cell Biol. 9, 505–512. doi: 10.1016/S0955-0674(97)80026-9
Headland, S. E., and Norling, L. V. (2015). The resolution of inflammation: 
principles and challenges. Semin. Immunol. 27, 149–160. doi: 10.1016/j.
smim.2015.03.014
Headland, S. E., Jones, H. R., Norling, L. V., Kim, A., Souza, P. R., Corsiero, E., 
et al. (2015). Neutrophil-derived microvesicles enter cartilage and protect the 
joint in inflammatory arthritis. Sci. Transl. Med. 7, 315ra190–315ra190. doi: 
10.1126/scitranslmed.aac5608
Hedlund, M., Stenqvist, A.-C., Nagaeva, O., Kjellberg, L., Wulff, M., Baranov, V., et al. 
(2009). Human placenta expresses and secretes NKG2D ligands via exosomes that 
down-modulate the cognate receptor expression: Evidence for Immunosuppressive 
Function. J. Immunol. 183, 340–351. doi: 10.4049/jimmunol.0803477
Heemskerk, J. W. M., Vuist, W. M. J., Feijge, M. A. H., Reutelingsperger, C. 
P.  M., and Lindhout, T. (1997). Collagen but not fibrinogen surfaces induce 
Bleb formation, exposure of phosphatidylserine, and procoagulant activity 
of adherent platelets: Evidence for regulation by protein tyrosine kinase-
dependent Ca2+ responses. Blood 90, 2615–2625. doi: 10.1182/blood.
V90.7.2615.2615_2615_2625
Heiss, C., Amabile, N., Lee, A. C., Real, W. M., Schick, S. F., Lao, D., et al. (2008). 
Brief secondhand smoke exposure depresses endothelial progenitor cells 
activity and endothelial function. sustained vascular injury and blunted 
nitric oxide production. J. Am. Coll. Cardiol. 51, 1760–1771. doi: 10.1016/j.
jacc.2008.01.040
Hess, C., Sadallah, S., Hefti, A., Landmann, R., and Schifferdi, J. A. (1998). 
Ectosomes released by human neutrophils are specialized functional units. 
Mol. Immunol. 35, 354. doi: 10.1016/s0161-5890(98)90627-7
Hessvik, N. P., Øverbye, A., Brech, A., Torgersen, M. L., Jakobsen, I. S., Sandvig, K., 
et al. (2016). PIKfyve inhibition increases exosome release and induces secretory 
autophagy. Cell. Mol. Life Sci. 73, 4717–4737. doi: 10.1007/s00018-016-2309-8
Holvoet, P., Vanhaverbeke, M., Bloch, K., Baatsen, P., Sinnaeve, P., and Janssens, S. 
(2016). Low MT-CO1 in monocytes and microvesicles is associated with 
outcome in patients with coronary artery disease. J. Am. Heart Assoc. 5, 
e004207. doi: 10.1161/JAHA.116.004207
Hong, Y., Eleftheriou, D., Hussain, A. A. K., Price-Kuehne, F. E., Savage, C. O., 
Jayne, D., et al. (2012). Anti-neutrophil cytoplasmic antibodies stimulate 
release of neutrophil microparticles. J. Am. Soc Nephrol. 23, 49–62. doi: 
10.1681/ASN.2011030298
Hosseinkhani, B., Kuypers, S., van den Akker, N. M. S., Molin, D. G. M., and 
Michiels, L. (2018). Extracellular vesicles work as a functional inflammatory 
mediator between vascular endothelial cells and immune Cells. Front. 
Immunol. 9, 1789. doi: 10.3389/fimmu.2018.01789
Huber, J., Vales, A., Mitulovic, G., Blumer, M., Schmid, R., Witztum, J. L., et al. 
(2002). Oxidized membrane vesicles and blebs from apoptotic cells contain 
biologically active oxidized phospholipids that induce monocyte-endothelial 
interactions. Arterioscler. Thromb. Vasc. Biol. 22, 101–107. doi: 10.1161/
hq0102.101525
Hunter, M. P., Ismail, N., Zhang, X., Aguda, B. D., Lee, E. J., Yu, L., et al. (2008). 
Detection of microRNA Expression in Human Peripheral Blood Microvesicles. 
PloS ONE 3, e3694. doi: 10.1371/journal.pone.0003694
Hyenne, V., Ghoroghi, S., Collot, M., Bons, J., Follain, G., Harlepp, S., et al. 
(2019). Studying the fate of tumor extracellular vesicles at high spatiotemporal 
resolution using the zebrafish embryo. Dev. Cell 48, 554–572.e7. doi: 10.1016/j.
devcel.2019.01.014
Ishizaki, T., Maekawa, M., Fujisawa, K., Okawa, K., Iwamatsu, A., Fujita, A., et al. 
(1996). The small GTP-binding protein Rho binds to and activates a 160 kDa 
Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 15, 
1885–1893. doi: 10.1002/j.1460-2075.1996.tb00539.x
Italiano, J. E., Mairuhu, A. T., and Flaumenhaft, R. (2010). Clinical relevance of 
microparticles from platelets and megakaryocytes. Curr. Opin. Hematol. 17, 
578–584. doi: 10.1097/MOH.0b013e32833e77ee
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1479
The Contrasting Role of Extracellular VesiclesOggero et al.
19
Janowska-Wieczorek, A., Wysoczynski, M., Kijowski, J., Marquez-Curtis, L., 
Machalinski, B., Ratajczak, J., et al. (2005). Microvesicles derived from activated 
platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113, 
752–760. doi: 10.1002/ijc.20657
Jansen, F., Yang, X., Hoyer, F. F., Paul, K., Heiermann, N., Becher, M. U., et al. (2012). 
Endothelial microparticle uptake in target cells is annexin I/phosphatidylserine 
receptor dependent and prevents apoptosis. Arterioscler. Thromb. Vasc. Biol. 32, 
1925–1935. doi: 10.1161/ATVBAHA.112.253229
Jansen, F., Yang, X., Hoelscher, M., Cattelan, A., Schmitz, T., Proebsting, S., 
et  al. (2013). Endothelial microparticle-mediated transfer of microRNA-126 
promotes vascular endothelial cell repair via spred1 and is abrogated in 
glucose-damaged endothelial microparticles. Circulation 128, 2026–2038. doi: 
10.1161/CIRCULATIONAHA.113.001720
Jansen, F., Yang, X., Proebsting, S., Hoelscher, M., Przybilla, D., Baumann, K., 
et al. (2014). MicroRNA expression in circulating microvesicles predicts 
cardiovascular events in patients with coronary artery disease. J. Am. Heart 
Assoc. 27;3 (6), e001249. doi: 10.1161/JAHA.114.001249
Jansen, F., Yang, X., Baumann, K., Przybilla, D., Schmitz, T., Flender, A., et al. 
(2015). Endothelial microparticles reduce ICAM-1 expression in a microRNA-
222-dependent mechanism. J. Cell. Mol. Med. 19, 2202–2214. doi: 10.1111/
jcmm.12607
Jansen, F., Stumpf, T., Proebsting, S., Franklin, B. S., Wenzel, D., Pfeifer, P., et al. 
(2017). Intercellular transfer of miR-126-3p by endothelial microparticles 
reduces vascular smooth muscle cell proliferation and limits neointima 
formation by inhibiting LRP6. J. Mol. Cell. Cardiol. 104, 43–52. doi: 10.1016/j.
yjmcc.2016.12.005
Jeppesen, D. K., Fenix, A. M., Franklin, J. L., Higginbotham, J. N., Zhang, Q., 
Zimmerman, L. J., et al. (2019). Reassessment of exosome composition. Cell 
177, 428–445.e18. doi: 10.1016/j.cell.2019.02.029
Jimenez, J. J., Jy, W., Mauro, L. M., Soderland, C., Horstman, L. L., and Ahn, Y. S. 
(2003). Endothelial cells release phenotypically and quantitatively distinct 
microparticles in activation and apoptosis. Thromb. Res. 109, 175–180. doi: 
10.1016/S0049-3848(03)00064-1
Johnstone, R. M., Bianchini, A., and Teng, K. (1989). Reticulocyte maturation and 
exosome release: transferrin receptor containing exosomes shows multiple 
plasma membrane functions. Blood 74, 1844–1851. doi: papers3://publication/
uuid/308E8E64-F5F8-4023-A648-08B98C24F304
Jung, K. H., Chu, K., Lee, S. T., Park, H. K., Bahn, J. J., Kim, D. H., et al. (2009). 
Circulating endothelial microparticles as a marker of cerebrovascular disease. 
Ann. Neurol. 66, 191–199. doi: 10.1002/ana.21681
Kagawa, H., Komiyama, Y., Nakamura, S., Miyake, T., Miyazaki, Y., Hamamoto, K., 
et al. (1998). Expression of functional tissue factor on small vesicles of 
lipopolysaccharide-stimulated human vascular endothelial cells. Thromb. Res. 
91, 297–304. doi: 10.1016/S0049-3848(98)00108-X
Kajimoto, T., Okada, T., Miya, S., Zhang, L., and Nakamura, S. (2013). Ongoing 
activation of sphingosine 1-phosphate receptors mediates maturation of 
exosomal multivesicular endosomes. Nat. Commun. 4, 2712. doi: 10.1038/
ncomms3712
Kanhai, D. A., Visseren, F. L. J., Van Der Graaf, Y., Schoneveld, A. H., Catanzariti, 
L. M., Timmers, L., et al. (2013). Microvesicle protein levels are associated 
with increased risk for future vascular events and mortality in patients with 
clinically manifest vascular disease. Int. J. Cardiol. 168, 2358–2363. doi: 
10.1016/j.ijcard.2013.01.231
Kannan, M., Mohan, K. V. K., Kulkarni, S., and Atreya, C. (2009). Membrane 
array-based differential profiling of platelets during storage for 52 
miRNAs associated with apoptosis. Transfusion 49, 1443–1450. doi: 
10.1111/j.1537-2995.2009.02140.x
Kanuri, S. H., Ipe, J., Kassab, K., Gao, H., Liu, Y., Skaar, T. C., et al. (2018). Next 
generation MicroRNA sequencing to identify coronary artery disease patients 
at risk of recurrent myocardial infarction. Atherosclerosis 278, 232–239. doi: 
10.1016/j.atherosclerosis.2018.09.021
Khaspekova, S. G., Antonova, O. A., Shustova, O. N., Yakushkin, V. V., Golubeva, 
N. V., Titaeva, E. V., et al. (2016). Activity of tissue factor in microparticles 
produced in vitro by endothelial cells, monocytes, granulocytes, and platelets. 
Biochem. 81, 114–121. doi: 10.1134/S000629791602005X
Kim, H. K., Song, K. S., Chung, J. H., Lee, K. R., and Lee, S. N. (2004). Platelet 
microparticles induce angiogenesis in vitro. Br. J. Haematol. 124, 376–384. doi: 
10.1046/j.1365-2141.2003.04773.x
Kim, S.-H., Lechman, E. R., Bianco, N., Menon, R., Keravala, A., Nash, J., et al. 
(2005). Exosomes derived from IL-10-Treated dendritic cells can suppress 
inflammation and collagen-induced arthritis. J. Immunol. 174, 6440–6448. doi: 
10.4049/jimmunol.174.10.6440
Kim, S. H., Bianco, N. R., Shufesky, W. J., Morelli, A. E., and Robbins, P. D. (2007). 
MHC Class II + Exosomes in plasma suppress inflammation in an antigen-
specific and fas ligand/fas-dependent manner. J. Immunol. 179, 2235–2241. doi: 
10.4049/jimmunol.179.4.2235
Koga, H., Sugiyama, S., Kugiyama, K., Watanabe, K., Fukushima, H., Tanaka, T., 
et al. (2005). Elevated levels of VE-cadherin-positive endothelial microparticles 
in patients with type 2 diabetes mellitus and coronary artery disease. J. Am. 
Coll. Cardiol. 45, 1622–1630. doi: 10.1016/j.jacc.2005.02.047
Koga, H., Sugiyama, S., Kugiyama, K., Fukushima, H., Watanabe, K., Sakamoto, T., 
et al. (2006). Elevated levels of remnant lipoproteins are associated with 
plasma platelet microparticles in patients with type-2 diabetes mellitus without 
obstructive coronary artery disease. Eur. Heart J. 27, 817–823. doi: 10.1093/
eurheartj/ehi746
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., 
et al. (2016). Proteomic comparison defines novel markers to characterize 
heterogeneous populations of extracellular vesicle subtypes. Proc. Natl. Acad. 
Sci. U. S. A. 113, E968–E977. doi: 10.1073/pnas.1521230113
Kuravi, S. J., Harrison, P., Rainger, G. E., and Nash, G. B. (2019). Ability of 
platelet-derived extracellular vesicles to promote neutrophil-endothelial cell 
interactions. Inflammation 42, 290–305. doi: 10.1007/s10753-018-0893-5
Lacroix, R., Sabatier, F., Mialhe, A., Basire, A., Pannell, R., Borghi, H., et al. 
(2007). Activation of plasminogen into plasmin at the surface of endothelial 
microparticles: a mechanism that modulates angiogenic properties of 
endothelial progenitor cells in vitro. Blood 110, 2432–2439. doi: 10.1182/
blood-2007-02-069997
Laffont, B., Corduan, A., Plé, H., Duchez, A.-C., Cloutier, N., Boilard, E., et al. 
(2013). Activated platelets can deliver mRNA regulatory Ago2•microRNA 
complexes to endothelial cells via microparticles. Blood 122, 253–261. doi: 
10.1182/blood-2013-03-492801
Laffont, B., Corduan, A., Rousseau, M., Duchez, A. C., Lee, C. H. C., Boilard, E., 
et  al. (2016). Platelet microparticles reprogram macrophage gene expression 
and function. Thromb. Haemost. 115, 311–323. doi: 10.1160/TH15-05-0389
Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S. K., Choo, A., Chen, T. S., et al. (2010). 
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. 
Stem Cell Res. 4, 214–222. doi: 10.1016/j.scr.2009.12.003
Landry, P., Plante, I., Ouellet, D. L., Perron, M. P., Rousseau, G., and Provost, P. 
(2009). Existence of a microRNA pathway in anucleate platelets. Nat. Struct. 
Mol. Biol. 16, 961–966. doi: 10.1038/nsmb.1651
Lee, Y. J., Jy, W., Horstman, L. L., Janania, J., Reyes, Y., Kelley, R. E., et al. 
(1993). Elevated platelet microparticles in transient ischemic attacks, 
lacunar infarcts, and multiinfarct dementias. Thromb. Res. 72, 295–304. doi: 
10.1016/0049-3848(93)90138-E
Leung, T., Chen, X. Q., Manser, E., and Lim, L. (1996). The p160 RhoA-binding 
kinase ROK alpha is a member of a kinase family and is involved in the 
reorganization of the cytoskeleton. Mol. Cell. Biol. 16, 5313–5327. doi: 10.1128/
mcb.16.10.5313
Li, B., Antonyak, M. A., Zhang, J., and Cerione, R. A. (2012a). RhoA triggers a 
specific signaling pathway that generates transforming microvesicles in cancer 
cells. Oncogene 31, 4740–4749. doi: 10.1038/onc.2011.636
Li, X., Li, J.-J., Yang, J.-Y., Wang, D.-S., Zhao, W., Song, W.-J., et al. (2012b). 
Tolerance induction by exosomes from immature dendritic cells and rapamycin 
in a mouse cardiac allograft model. PloS One 7, e44045. doi: 10.1371/journal.
pone.0044045
Li, J., Zhang, Y., Liu, Y., Dai, X., Li, W., Cai, X., et al. (2013a). Microvesicle-mediated 
transfer of microRNA-150 from monocytes to endothelial cells promotes 
angiogenesis. J. Biol. Chem. 288, 23586–23596. doi: 10.1074/jbc.M113.489302
Li, J., Zhang, Y., Liu, Y., Dai, X., Li, W., Cai, X., et al. (2013b). Microvesicle-
mediated transfer of MicroRNA-150 from monocytes to endothelial cells 
promotes angiogenesis. J. Biol. Chem. 288, 23586–23596. doi: 10.1074/jbc.
M113.489302
Li, M., Zhang, X., Yu, J., Wu, X., and Sun, L. (2017). Monocyte-derived procoagulant 
microvesicles induced by high glucose can be attenuated by the antioxidant 
N-Acetyl-L-Cysteine, partly through the P38/MAPK pathway. Metab. Syndr. 
Relat. Disord. 15, 521–526. doi: 10.1089/met.2017.0089
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1479
The Contrasting Role of Extracellular VesiclesOggero et al.
20
Lim, K., Sumagin, R., and Hyun, Y.-M. (2013). Extravasating neutrophil-derived 
microparticles preserve vascular barrier function in inflamed tissue. Immune 
Netw. 13, 102. doi: 10.4110/in.2013.13.3.102
Lindemann, S., Tolley, N. D., Dixon, D. A., McIntyre, T. M., Prescott, S. M., 
Zimmerman, G. A., et al. (2001). Activated platelets mediate inflammatory 
signaling by regulated interleukin 1β synthesis. J. Cell Biol. 154, 485–490. doi: 
10.1083/jcb.200105058
Lorincz, A. M., Schutte, M., Timar, C. I., Veres, D. S., Kittel, A., McLeish, K. R., 
et al. (2015). Functionally and morphologically distinct populations of 
extracellular vesicles produced by human neutrophilic granulocytes. J. Leukoc. 
Biol. 98, 583–589. doi: 10.1189/jlb.3vma1014-514r
Ludwig, A. K., and Giebel, B. (2012). Exosomes: small vesicles participating in 
intercellular communication. Int. J. Biochem. Cell Biol. 44, 11–15. doi: 10.1016/j.
biocel.2011.10.005
Luther, K. M., Haar, L., McGuinness, M., Wang, Y., Lynch, T. L.IV, Phan,  A., 
et  al. (2018). Exosomal miR-21a-5p mediates cardioprotection by 
mesenchymal stem cells. J. Mol. Cell. Cardiol. 119, 125–137. doi: 10.1016/j.
yjmcc.2018.04.012
Ma, X., Becker Buscaglia, L. E., Barker, J. R., and Li, Y. (2011). MicroRNAs in NF- B 
signaling. J. Mol. Cell Biol. 3, 159–166. doi: 10.1093/jmcb/mjr007
Mack, M., Kleinschmidt, A., Brühl, H., Klier, C., Nelson, P. J., Cihak, J., et al. 
(2000). Transfer of the chemokine receptor CCR5 between cells by membrane-
derived microparticles: A mechanism for cellular human immunodeficiency 
virus 1 infection. Nat. Med. 6, 769–775. doi: 10.1038/77498
MacKie, A. R., Klyachko, E., Thorne, T., Schultz, K. M., Millay, M., Ito, A., et al. 
(2012). Sonic hedgehog-modified human CD34+ cells preserve cardiac 
function after acute myocardial infarction. Circ. Res. 111, 312–321. doi: 
10.1161/CIRCRESAHA.112.266015
Majka, M., Kijowski, J., Lesko, E., Zupanska, B., and Ratajczak, M. Z. (2007). 
Evidence that platelet-derived microvesicles may transfer platelet-specific 
immunoreactive antigens to the surface of endothelial cells and CD34+ 
hematopoietic stem/progenitor cells - Implication for the pathogenesis of 
immune thrombocytopenias. Folia Histochem. Cytobiol. 45, 27–32.
Maki, M., Takahara, T., and Shibata, H. (2016). Multifaceted roles of ALG-2 in 
Ca2+-regulated membrane trafficking. Int. J. Mol. Sci. 17, 1401. doi: 10.3390/
ijms17091401
Marrachelli, V. G., Mastronardi, M. L., Sarr, M., Soleti, R., Leonetti, D., 
Martínez, M. C., et al. (2013). Sonic hedgehog carried by microparticles corrects 
angiotensin II-Induced Hypertension and Endothelial Dysfunction in Mice. PloS 
One 8, e72861. doi: 10.1371/journal.pone.0072861
Mastronardi, M. L., Mostefai, H. A., Soleti, R., Agouni, A., Martínez, M. C., 
and Andriantsitohaina, R. (2011). Microparticles from apoptotic monocytes 
enhance nitrosative stress in human endothelial cells. Fundam. Clin. Pharmacol. 
25, 653–660. doi: 10.1111/j.1472-8206.2010.00898.x
Matsui, T., Amano, M., Yamamoto, T., Chihara, K., Nakafuku, M., Ito, M., et al. 
(1996). Rho-associated kinase, a novel serine/threonine kinase, as a putative 
target for small GTP binding protein Rho. EMBO J. 15, 2208–2216. doi: 
10.1002/j.1460-2075.1996.tb00574.x
Mause, S. F., Von Hundelshausen, P., Zernecke, A., Koenen, R. R., and Weber, C. 
(2005). Platelet microparticles: A transcellular delivery system for RANTES 
promoting monocyte recruitment on endothelium. Arterioscler. Thromb. Vasc. 
Biol. 25, 1512–1518. doi: 10.1161/01.ATV.0000170133.43608.37
Mayourian, J., Ceholski, D. K., Gorski, P. A., Mathiyalagan, P., Murphy, J. F., 
Salazar, S. I., et al. (2018). Exosomal microRNA-21-5p mediates mesenchymal 
stem cell paracrine effects on human cardiac tissue contractility. Circ. Res. 122, 
933–944. doi: 10.1161/CIRCRESAHA.118.312420
Mesri, M., and Altieri, D. C. (1998). Endothelial cell activation by leukocyte 
microparticles. J. Immunol. 161, 4382–4387.
Mitra, S., Wewers, M. D., and Sarkar, A. (2015). Mononuclear phagocyte-derived 
microparticulate Caspase-1 induces pulmonary vascular endothelial cell 
injury. PloS One 10, e0145607. doi: 10.1371/journal.pone.0145607
Morel, O., Toti, F., Hugel, B., Bakouboula, B., Camoin-Jau, L., Dignat-George, F., 
et al. (2006). Procoagulant Microparticles. Arterioscler. Thromb. Vasc. Biol. 26, 
2594–2604. doi: 10.1161/01.ATV.0000246775.14471.26
Morel, O., Ohlmann, P., Epailly, E., Bakouboula, B., Zobairi, F., Jesel, L., et al. 
(2008). Endothelial cell activation contributes to the release of procoagulant 
microparticles during acute cardiac allograft rejection. J. Hear. Lung Transplant. 
27, 38–45. doi: 10.1016/j.healun.2007.09.031
Morel, O., Toti, F., Morel, N., and Freyssinet, J.-M. (2009). Microparticles 
in endothelial cell and vascular homeostasis: are they really noxious? 
Haematologica 94, 313–317. doi: 10.3324/haematol.2009.003657
Mostefai, H. A., Meziani, F., Mastronardi, M. L., Agouni, A., Heymes, C., 
Sargentini, C., et al. (2008). Circulating microparticles from patients with 
septic shock exert protective role in vascular function. Am. J. Respir. Crit. Care 
Med. 178, 1148–1155. doi: 10.1164/rccm.200712-1835OC
Nadkarni, S., Lashin, H., Hollywood, J., Dasgupta, B., Mason, J. C., and Perretti, M. 
(2019). Identification of an activated neutrophil phenotype in polymyalgia 
rheumatica during steroid treatment: A potential involvement of immune cell 
cross-talk. Clin. Sci. 133, 839–851. doi: 10.1042/CS20180415
Nazari-Jahantigh, M., Wei, Y., Noels, H., Akhtar, S., Zhou, Z., Koenen, R. R., 
et  al. (2012). MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in 
macrophages. J. Clin. Invest. 122, 4190–4202. doi: 10.1172/JCI61716
Ng, Y. H., Rome, S., Jalabert, A., Forterre, A., Singh, H., Hincks, C. L., et al. (2013). 
Endometrial exosomes/microvesicles in the uterine microenvironment: a new 
paradigm for embryo-endometrial cross talk at implantation. PloS One 8, 
e58502. doi: 10.1371/journal.pone.0058502
Nguyen, M.-A., Karunakaran, D., Geoffrion, M., Cheng, H. S., Tandoc, K., 
Perisic Matic, L., et al. (2018). Extracellular vesicles secreted by atherogenic 
macrophages transfer MicroRNA to inhibit cell migration. Arterioscler. 
Thromb. Vasc. Biol. 38, 49–63. doi: 10.1161/ATVBAHA.117.309795
Njock, M. S., Cheng, H. S., Dang, L. T., Nazari-Jahantigh, M., Lau, A. C., 
Boudreau,  E., et al. (2015). Endothelial cells suppress monocyte activation 
through secretion of extracellular vesicles containing antiinflammatory 
microRNAs. Blood 125, 3202–3212. doi: 10.1182/blood-2014-11-611046
Nomura, S., Suzuki, M., Katsura, K., Xie, G. L., Miyazaki, Y., Miyake, T., et al. 
(1995). Platelet-derived microparticles may influence the development 
of atherosclerosis in diabetes mellitus. Atherosclerosis 116, 235–240. doi: 
10.1016/0021-9150(95)05551-7
Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M., Iwasaka, T., and Fukuhara, S. 
(2004). Activated platelet and oxidized LDL induce endothelial membrane 
vesiculation: clinical significance of endothelial cell-derived microparticles 
in patients with type 2 diabetes. Clin. Appl. Thromb. 10, 205–215. doi: 
10.1177/107602960401000302
Nomura, S. (2001). High-shear-stress-induced activation of platelets and 
microparticles enhances expression of cell adhesion molecules in 
THP-1 and endothelial cells. Atherosclerosis 158, 277–287. doi: 10.1016/
S0021-9150(01)00433-6
Norling, L. V., Spite, M., Yang, R., Flower, R. J., Perretti, M., and Serhan, C. N. 
(2011). Cutting edge: humanized nano-proresolving medicines mimic 
inflammation-resolution and enhance wound healing. J. Immunol. 186, 5543–
5547. doi: 10.4049/jimmunol.1003865
Odintsova, E., Van Niel, G., Conjeaud, H., Raposo, G., Iwamoto, R., Mekada, E., 
et al. (2013). Metastasis suppressor tetraspanin CD82/KAI1 regulates 
ubiquitylation of epidermal growth factor receptor. J. Biol. Chem. 288, 26323–
26334. doi: 10.1074/jbc.M112.439380
Ong, S. G., Lee, W. H., Huang, M., Dey, D., Kodo, K., Sanchez-Freire, V., et al. 
(2014). Cross talk of combined gene and cell therapy in ischemic heart disease 
role of exosomal MicroRNA transfer. Circulation 130, S60–S69. doi: 10.1161/
CIRCULATIONAHA.113.007917
Ou, Z. J., Chang, F. J., Luo, D., Liao, X. L., Wang, Z. P., Zhang, X., et al. (2011). 
Endothelium-derived microparticles inhibit angiogenesis in the heart and 
enhance the inhibitory effects of hypercholesterolemia on angiogenesis. 
Am. J. Physiol. - Endocrinol. Metab. 300, 661–668. doi: 10.1152/
ajpendo.00611.2010
Owens, A. P., and Mackman, N. (2011). Microparticles in Hemostasis and 
Thrombosis. Circ. Res. 108, 1284–1297. doi: 10.1161/CIRCRESAHA.110.233056
Pérez-Casal, M., Downey, C., Cutillas-Moreno, B., Zuzel, M., Fukudome, K., and 
Ton, C. H. (2009). Microparticle-associated endothelial protein C receptor and 
the induction of cytoprotective and anti-inflammatory effects. Haematologica 
94, 387–394. doi: 10.3324/haematol.13547
Pan, Y., Liang, H., Liu, H., Li, D., Chen, X., Li, L., et al. (2014). platelet-secreted 
MicroRNA-223 promotes endothelial cell apoptosis induced by advanced 
glycation end products via targeting the insulin-like growth factor 1 receptor. J. 
Immunol. 192, 437–446. doi: 10.4049/jimmunol.1301790
Pasquet, J.-M., Dachary-Prigent, J., and Nurden, A. T. (1998). Microvesicle release 
is associated with extensive protein tyrosine dephosphorylation in platelets 
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1479
The Contrasting Role of Extracellular VesiclesOggero et al.
21
stimulated by A23187 or a mixture of thrombin and collagen. Biochem. J. 333, 
591–599. doi: 10.1042/bj3330591
Perez-Pujol, S., Marker, P. H., and Key, N. S. (2007). Platelet microparticles are 
heterogeneous and highly dependent on the activation mechanism: studies 
using a new digital flow cytometer. Cytom. Part A 71A, 38–45. doi: 10.1002/
cyto.a.20354
Peterson, D. B., Sander, T., Kaul, S., Wakim, B. T., Halligan, B., Twigger, S., et al. (2008). 
Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial 
microparticles. Proteomics 8, 2430–2446. doi: 10.1002/pmic.200701029
Pfrieger, F. W., and Vitale, N. (2018). Cholesterol and the journey of extracellular 
vesicles. J. Lipid Res. 59, 2255–2261. doi: 10.1194/jlr.R084210
Pierce, G. F. (1989). Platelet-derived growth factor and transforming growth 
factor-beta enhance tissue repair activities by unique mechanisms. J. Cell Biol. 
109, 429–440. doi: 10.1083/jcb.109.1.429
Pinto, S. M., Nirujogi, R. S., Rojas, P. L., Patil, A. H., Manda, S. S., Subbannayya, Y., 
et al. (2015). Quantitative phosphoproteomic analysis of IL-33-mediated 
signaling. Proteomics 15, 532–544. doi: 10.1002/pmic.201400303
Preston, R. A., Jy, W., Jimenez, J. J., Mauro, L. M., Horstman, L. L., Valle, M., et al. 
(2003). Effects of severe hypertension on endothelial and platelet microparticles. 
Hypertension 41, 211–217. doi: 10.1161/01.HYP.0000049760.15764.2D
Rauschenberger, L., Staar, D., Thom, K., Scharf, C., Venz, S., Homuth, G., et al. 
(2016). Exosomal particles secreted by prostate cancer cells are potent mRNA 
and protein vehicles for the interference of tumor and tumor environment. 
Prostate 76, 409–424. doi: 10.1002/pros.23132
Rectenwald, J. E., Myers, D. D., Hawley, A. E., Longo, C., Henke, P. K., Guire, K. E., 
et al. (2005). D-dimer, P-selectin, and microparticles: novel markers to predict 
deep venous thrombosis: a pilot study. Thromb. Haemost. 94, 1312–1317. doi: 
10.1160/TH05-06-0426
Rhys, H. I., Dell’Accio, F., Pitzalis, C., Moore, A., Norling, L. V., and Perretti, M. 
(2018). Neutrophil microvesicles from healthy control and rheumatoid arthritis 
patients prevent the inflammatory activation of macrophages. EBioMedicine 
29, 60–69. doi: 10.1016/j.ebiom.2018.02.003
Ridger, V. C., Boulanger, C. M., Angelillo-Scherrer, A., Badimon, L., Blanc-
Brude,  O., Bochaton-Piallat, M. L., et al. (2017). Microvesicles in vascular 
homeostasis and diseases position paper of the european society of cardiology 
(ESC) working group on atherosclerosis and vascular biology. Thromb. 
Haemost. 117, 1296–1316. doi: 10.1160/TH16-12-0943
Ross, R. (1986). The pathogenesis of atherosclerosis — an update. N. Engl. J. Med. 
314, 488–500. doi: 10.1056/NEJM198602203140806
Sáez, T., de Vos, P., Kuipers, J., Sobrevia, L., and Faas, M. M. (2019). Exosomes 
derived from monocytes and from endothelial cells mediate monocyte and 
endothelial cell activation under high d-glucose conditions. Immunobiology 
224, 325–333. doi: 10.1016/j.imbio.2019.02.004
Sabatier, F., Roux, V., Anfosso, F., Camoin, L., Sampol, J., and Dignat-George, F. 
(2002). Interaction of endothelial microparticles with monocytic cells in vitro 
induces tissue factor–dependent procoagulant activity. Blood 99, 3962–3970. 
doi: 10.1182/blood.V99.11.3962
Sadallah, S., Amicarella, F., Eken, C., Iezzi, G., and Schifferli, J. (2014). Ectosomes 
released by platelets induce differentiation of CD4+ T cells into T regulatory 
cells. Thromb. Haemost. 112, 1219–1229. doi: 10.1160/th14-03-0281
Sarkar, A., Mitra, S., Mehta, S., Raices, R., and Wewers, M. D. (2009). Monocyte 
derived microvesicles deliver a cell death message via encapsulated caspase-1. 
PloS One 4, e7140. doi: 10.1371/journal.pone.0007140
Shet, A. S., Aras, O., Gupta, K., Hass, M. J., Rausch, D. J., Saba, N., et al. (2003). 
Sickle blood contains tissue factor-positive microparticles derived from 
endothelial cells and monocytes. Blood 102, 2678–2683. doi: 10.1182/
blood-2003-03-0693
Shimazu, T., Inami, N., Satoh, D., Kajiura, T., Yamada, K., Iwasaka, T., et al. (2009). 
Effect of acarbose on platelet-derived microparticles, soluble selectins, and 
adiponectin in diabetic patients. J. Thromb. Thrombolysis 28, 429–435. doi: 
10.1007/s11239-008-0301-3
Shustova, O. N., Antonova, O. A., Golubeva, N. V., Khaspekova, S. G., 
Yakushkin, V. V., Aksuk, S. A., et al. (2017). Differential procoagulant activity of 
microparticles derived from monocytes, granulocytes, platelets and endothelial 
cells: impact of active tissue factor. Blood Coagul. Fibrinolysis 28, 373–382. doi: 
10.1097/MBC.0000000000000609
Šimák, J., Holada, K., and Vostal, J. G. (2002). Release of annexin V-binding 
membrane microparticles from cultured human umbilical vein endothelial 
cells after treatment with camptothecin. BMC Cell Biol. 3, 11. doi: 
10.1186/1471-2121-3-11
Stehouwer, C. D. A., Henry, R. M. A., and Ferreira, I. (2008). Arterial stiffness 
in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. 
Diabetologia 51, 527–539. doi: 10.1007/s00125-007-0918-3
Steogonekpień, E., Stankiewicz, E., Zalewski, J., Godlewski, J., Zmudka, K., and 
Wybrańska, I. (2012). Number of microparticles generated during acute 
myocardial infarction and stable angina correlates with platelet activation. 
Arch. Med. Res. 43, 31–35. doi: 10.1016/j.arcmed.2012.01.006
Stojkovic, S., Thulin, Å., Hell, L., Thaler, B., Rauscher, S., Baumgartner, J., et al. 
(2017). IL-33 stimulates the release of procoagulant microvesicles from human 
monocytes and differentially increases tissue factor in human monocyte 
subsets. Thromb. Haemost. 117, 1379–1390. doi: 10.1160/TH16-10-0784
Stuffers, S., Sem Wegner, C., Stenmark, H., and Brech, A. (2009). Multivesicular 
endosome biogenesis in the absence of ESCRTs. Traffic 10, 925–937. doi: 
10.1111/j.1600-0854.2009.00920.x
Suades, R., Padró, T., Vilahur, G., and Badimon, L. (2012). Circulating and platelet-
derived microparticles in human blood enhance thrombosis on atherosclerotic 
plaques. Thromb. Haemost. 108, 1208–1219. doi: 10.1160/TH12-07-0486
Sugimoto, M. A., Sousa, L. P., Pinho, V., Perretti, M., and Teixeira, M. M. (2016). 
Resolution of inflammation: what controls its onset? Front. Immunol. 7, 160. 
doi: 10.3389/fimmu.2016.00160
Sun, C., Feng, S.-B., Cao, Z.-W., Bei, J.-J., Chen, Q., Zhao, W.-B., et al. (2017). 
Up-Regulated Expression of Matrix Metalloproteinases in Endothelial Cells 
Mediates Platelet Microvesicle-Induced Angiogenesis. Cell. Physiol. Biochem. 
41, 2319–2332. doi: 10.1159/000475651
Suzuki, J., Umeda, M., Sims, P. J., and Nagata, S. (2010). Calcium-dependent 
phospholipid scrambling by TMEM16F. Nature 468, 834–840. doi: 10.1038/
nature09583
Szotowski, B., Antoniak, S., Goldin-Lang, P., Tran, Q. V., Pels, K., Rosenthal, P., 
et al. (2007). Antioxidative treatment inhibits the release of thrombogenic tissue 
factor from irradiation- and cytokine-induced endothelial cells. Cardiovasc. 
Res. 73, 806–812. doi: 10.1016/j.cardiores.2006.12.018
Tabet, F., Vickers, K. C., Cuesta Torres, L. F., Wiese, C. B., Shoucri, B. M., Lambert, G., 
et al. (2014). HDL-transferred microRNA-223 regulates ICAM-1 expression in 
endothelial cells. Nat. Commun. 5, 3292. doi: 10.1038/ncomms4292
Tamai, K., Tanaka, N., Nakano, T., Kakazu, E., Kondo, Y., Inoue, J., et al. (2010). 
Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein. 
Biochem. Biophys. Res. Commun. 399, 384–390. doi: 10.1016/j.bbrc.2010.07.083
Tang, N., Sun, B., Gupta, A., Rempel, H., and Pulliam, L. (2016). Monocyte 
exosomes induce adhesion molecules and cytokines via activation of NF-κB in 
endothelial cells. FASEB J. 30, 3097–3106. doi: 10.1096/fj.201600368RR
Taraboletti, G. (1990). Platelet thrombospondin modulates endothelial cell 
adhesion, motility, and growth: a potential angiogenesis regulatory factor. J. 
Cell Biol. 111, 765–772. doi: 10.1083/jcb.111.2.765
Thakur, B. K., Zhang, H., Becker, A., Matei, I., Huang, Y., Costa-Silva, B., et al. 
(2014). Double-stranded DNA in exosomes: a novel biomarker in cancer 
detection. Cell Res. 24, 766–769. doi: 10.1038/cr.2014.44
Ti, D., Hao, H., Tong, C., Liu, J., Dong, L., Zheng, J., et al. (2015). LPS-
preconditioned mesenchymal stromal cells modify macrophage polarization 
for resolution of chronic inflammation via exosome-shuttled let-7b. J. Transl. 
Med. 13, 308. doi: 10.1186/s12967-015-0642-6
Tian, F.-J., An, L.-N., Wang, G.-K., Zhu, J.-Q., Li, Q., Zhang, Y.-Y., et al. (2014). 
Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in 
atherogenesis. Cardiovasc. Res. 103, 100–110. doi: 10.1093/cvr/cvu070
Timár, C. I., Lorincz, á. M., Csépányi-Kömi, R., Vályi-Nagy, A., Nagy, G., Buzás, E. I., 
et al. (2013). Antibacterial effect of microvesicles released from human neutrophilic 
granulocytes. Blood 121, 510–518. doi: 10.1182/blood-2012-05-431114
Tschoepe, D., Roesen, P., Schwippert, B., and Gries, F. (1993). Platelets in diabetes: 
The role in the hemostatic regulation in atherosclerosis. Semin. Thromb. 
Hemost. 19, 122–128. doi: 10.1055/s-2007-994015
Tseliou, E., Fouad, J., Reich, H., Slipczuk, L., De Couto, G., Aminzadeh, M., et 
al. (2015). Fibroblasts rendered antifibrotic, antiapoptotic, and angiogenic by 
priming with cardiosphere-derived extracellular membrane Vesicles. J. Am. 
Coll. Cardiol. 66, 599–611. doi: 10.1016/j.jacc.2015.05.068
Tsimerman, G., Roguin, A., Bachar, A., Melamed, E., Brenner, B., and Aharon, A. 
(2011). Involvement of microparticles in diabetic vascular complications. 
Thromb. Haemost. 106, 310–321. doi: 10.1160/TH10-11-0712
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1479
The Contrasting Role of Extracellular VesiclesOggero et al.
22
Vagner, T., Chin, A., Mariscal, J., Bannykh, S., Engman, D. M., and Di Vizio, D. 
(2019). Protein Composition Reflects Extracellular Vesicle Heterogeneity. 
Proteomics 19, 1800167. doi: 10.1002/pmic.201800167
Vajen, T., Benedikter, B. J., Heinzmann, A. C. A., Vasina, E. M., Henskens,  Y., 
Parsons, M., et al. (2017). Platelet extracellular vesicles induce a pro-
inflammatory smooth muscle cell phenotype. J. Extracell. Vesicles 6, 1322454. 
doi: 10.1080/20013078.2017.1322454
Van der Pol, E., Böing, A. N., Harrison, P., Sturk, A., and Nieuwland, R. (2012). 
Classification, functions, and clinical relevance of extracellular vesicles. 
Pharmacol. Rev. 64, 676–705. doi: 10.1124/pr.112.005983
Van der Pol, E., Böing, A. N., Gool, E. L., and Nieuwland, R. (2016). Recent 
developments in the nomenclature, presence, isolation, detection and clinical 
impact of extracellular vesicles. J. Thromb. Haemost. 14, 48–56. doi: 10.1111/
jth.13190
Van Niel, G., D’Angelo, G., and Raposo, G. (2018). Shedding light on the cell 
biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228. doi: 
10.1038/nrm.2017.125
Vargas, A., Roux-Dalvai, F., Droit, A., and Lavoie, J.-P. (2016). Neutrophil-derived 
exosomes: a new mechanism contributing to airway smooth muscle remodeling. 
Am. J. Respir. Cell Mol. Biol. 55, 450–461. doi: 10.1165/rcmb.2016-0033OC
Varon, D., and Shai, E. (2015). Platelets and their microparticles as key players in 
pathophysiological responses. J. Thromb. Haemost. 13, S40–S46. doi: 10.1111/
jth.12976
Verbree-Willemsen, L., Zhang, Y.-N., Gijsberts, C. M., Schoneveld, A. H., Wang, 
J.-W., Lam, C. S. P., et al. (2018). LDL extracellular vesicle coagulation protein 
levels change after initiation of statin therapy. Findings from the METEOR 
trial. Int. J. Cardiol. 271, 247–253. doi: 10.1016/j.ijcard.2018.05.098
Vicencio, J. M., Yellon, D. M., Sivaraman, V., Das, D., Boi-Doku, C., Arjun, S., et al. 
(2015). Plasma exosomes protect the myocardium from ischemia-reperfusion 
injury. J. Am. Coll. Cardiol. 65, 1525–1536. doi: 10.1016/j.jacc.2015.02.026
Vinayagam, V., Bobby, Z., Habeebullah, S., Chaturvedula, L., and 
Bharadwaj,  S. K. (2016). Plasma markers of endothelial dysfunction in 
patients with hypertensive disorders of pregnancy: a pilot study in a 
South Indian population. J. Matern. Neonatal Med. 29, 2077–2082. doi: 
10.3109/14767058.2015.1075200
Wang, J. G., Williams, J. C., Davis, B. K., Jacobson, K., Doerschuk, C. M., 
Ting, J. P.-Y., et al. (2011). Monocytic microparticles activate endothelial 
cells in an IL-1β-dependent manner. Blood 118, 2366–2374. doi: 10.1182/
blood-2011-01-330878
Wang, X., Gu, H., Qin, D., Yang, L., Huang, W., Essandoh, K., et al. (2015a). Exosomal 
miR-223 contributes to mesenchymal stem cell-elicited cardioprotection in 
polymicrobial sepsis. Sci. Rep. 5, 13721. doi: 10.1038/srep13721
Wang, Y., Zhang, L., Li, Y., Chen, L., Wang, X., Guo, W., et al. (2015b). Exosomes/
microvesicles from induced pluripotent stem cells deliver cardioprotective 
miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. 
Int. J. Cardiol. 192, 61–69. doi: 10.1016/j.ijcard.2015.05.020
Warshaw, A. L., Laster, L., and Shulman, N. R. (1967). Protein synthesis by human 
platelets. J. Biol. Chem. 242, 2094–2097.
Whitlock, J. M., and Hartzell, H. C. (2017). Anoctamins/TMEM16 Proteins: 
chloride channels flirting with lipids and extracellular vesicles. Annu. Rev. 
Physiol. 79, 119–143. doi: 10.1146/annurev-physiol-022516-034031
Xin, H., Li, Y., Cui, Y., Yang, J. J., Zhang, Z. G., and Chopp, M. (2013). Systemic 
administration of exosomes released from mesenchymal stromal cells promote 
functional recovery and neurovascular plasticity after stroke in rats. J. Cereb. 
Blood Flow Metab. 33, 1711–1715. doi: 10.1038/jcbfm.2013.152
Yáñez-Mó, M., Siljander, P. R. M., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzas, 
E. I., et al. (2015). Biological properties of extracellular vesicles and their 
physiological functions. J. Extracell. Vesicles 4, 1–60. doi: 10.3402/jev.v4.27066
Yamamoto, S., Niida, S., Azuma, E., Yanagibashi, T., Muramatsu, M., Huang, T. T., 
et al. (2015). Inflammation-induced endothelial cell-derived extracellular 
vesicles modulate the cellular status of pericytes. Sci. Rep. 5, 8505. doi: 10.1038/
srep08505
Yang, C., Mwaikambo, B. R., Zhu, T., Gagnon, C., Lafleur, J., Seshadri, S., et al. (2008). 
Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative 
stress and negatively regulating VEGF-induced pathways. Am. J. Physiol. Integr. 
Comp. Physiol. 294, R467–R476. doi: 10.1152/ajpregu.00432.2007
Yang, X., Meng, S., Jiang, H., Zhu, C., and Wu, W. (2011). Exosomes derived from 
immature bone marrow dendritic cells induce tolerogenicity of intestinal 
transplantation in rats. J. Surg. Res. 171, 826–832. doi: 10.1016/j.jss.2010.05.021
Zampetaki, A., Willeit, P., Tilling, L., Drozdov, I., Prokopi, M., Renard, J. M., et al. 
(2012). Prospective study on circulating microRNAs and risk of myocardial 
infarction. J. Am. Coll. Cardiol. 60, 290–299. doi: 10.1016/j.jacc.2012.03.056
Zhang, B., Yin, Y., Lai, R. C., Tan, S. S., Choo, A. B. H., and Lim, S. K. (2014). 
Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells 
Dev. 23, 1233–1244. doi: 10.1089/scd.2013.0479
Zhang, Y., Chopp, M., Zhang, Z. G., Katakowski, M., Xin, H., Qu, C., et al. (2017). 
Systemic administration of cell-free exosomes generated by human bone 
marrow derived mesenchymal stem cells cultured under 2D and 3D conditions 
improves functional recovery in rats after traumatic brain injury. Neurochem. 
Int. 111, 69–81. doi: 10.1016/j.neuint.2016.08.003
Zitvogel, L., Regnault, A., Lozier, A., Wolfers, J., Flament, C., Tenza, D., et al. 
(1998). Eradication of established murine tumors using a novel cell-free 
vaccine: dendritic cell derived exosomes. Nat. Med. 4, 594–600. doi: 10.1038/
nm0598-594
Conflict of Interest: The authors declare that the research was conducted in the 
absence of any commercial or financial relationships that could be construed as a 
potential conflict of interest.
Copyright © 2019 Oggero, Austin-Williams and Norling. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) and the copyright owner(s) are credited and 
that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does 
not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org December 2019 | Volume 10 | Article 1479
